temozolomide has been researched along with Melanoma in 317 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma." | 9.69 | Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. ( Bai, X; Cheng, F; Chi, Z; Cui, C; Dai, J; Duan, R; Guo, J; Kong, Y; Li, C; Li, J; Li, S; Lian, B; Mao, L; Pang, Z; Sheng, X; Si, L; Tang, B; Wang, X; Wei, X; Wu, X; Xia, F; Xu, H; Yan, X; Yang, Y; Zhang, C; Zhou, L, 2023) |
| " The aim of this phase I study was to determine the maximum tolerated dose of the combination of TPI 287 and temozolomide in metastatic melanoma." | 9.22 | A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. ( Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP, 2016) |
| "In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily." | 9.20 | Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. ( Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M, 2015) |
| "In this phase 1b study, patients with stage 4 or unresectable stage 3 melanoma were treated with escalating doses of lenvatinib (once daily) and temozolomide (TMZ) (days 1-5) in 28-day cycles, to determine the maximum tolerated dose (MTD) of the combination." | 9.20 | Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. ( Andresen, C; Falchook, GS; George, GC; Hong, DS; Kim, KB; Kurzrock, R; Kwak, J; Nemunaitis, J; Nguyen, LM; O'Brien, JP; Ren, M; Xu, L, 2015) |
| "We conducted a single-arm phase II multi-institution cooperative group study to assess the antitumor activity and safety profile of the combination of TMZ and the rapamycin derivative everolimus in patients with metastatic unresectable malignant melanoma." | 9.19 | Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. ( Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M, 2014) |
| "This study showed that temozolomide (150-200 mg/m(2)/day) can safely be given with a PARP inhibitory dose of rucaparib, increasing progression-free survival over historical controls in metastatic melanoma patients." | 9.17 | A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. ( Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH, 2013) |
| "Patients with mucosal melanoma in stage II/III after surgery were randomized into three groups: observation group (group A, surgery alone), HDI group (group B, treated with 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 × 10(6) U IFN-α2b), and temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2)) group (group C)." | 9.17 | Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B, 2013) |
| "The combination of oblimersen, temozolomide, and nab-paclitaxel was well tolerated and demonstrated encouraging activity in patients with advanced melanoma." | 9.17 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. ( Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y, 2013) |
| "Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma." | 9.17 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ( Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013) |
| "Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10 mg/kg body weight i." | 9.16 | First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). ( Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R, 2012) |
| "To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma." | 9.16 | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. ( Bastholt, L; Cantarini, M; Dummer, R; Hersey, P; Kemsley, K; Kirkwood, JM; Larkin, J; Middleton, M; Robert, C; Sosman, J; Zazulina, V, 2012) |
| "The study is a proof-of-principle trial evaluating toxicity, immune response, and clinical response in melanoma patients after combined therapy with temozolomide and the telomerase peptide vaccine GV1001." | 9.15 | Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. ( Aamdal, S; Dueland, S; Gaudernack, G; Julsrud, L; Kyte, JA; Trachsel, S, 2011) |
| "To compare the efficacy of an extended schedule escalated dose of temozolomide versus standard dose dacarbazine in a large population of patients with stage IV melanoma." | 9.15 | Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ( Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U, 2011) |
| "This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients." | 9.15 | Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. ( Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A, 2011) |
| "In a search for more effective combination chemotherapy for the treatment of metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel, temozolomide, and cisplatin." | 9.14 | Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. ( Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE, 2009) |
| "We evaluated the pharmacodynamic effects of the O(6)-methylguanine-DNA methyltransferase (MGMT) inactivator lomeguatrib (LM) on patients with melanoma in two clinical trials." | 9.14 | O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. ( Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ, 2009) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 9.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "Patients must have had stage IV cutaneous melanoma, no active brain metastases, Zubrod PS 0-1, up to 1 prior systemic therapy excluding thalidomide, temozolomide, or dacarbazine, adequate organ function, and given informed consent." | 9.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-kappaB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets." | 9.14 | A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. ( Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y, 2010) |
| "Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma." | 9.14 | Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. ( Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E, 2010) |
| "We treated melanoma patients with temozolomide (TMZ) in the neoadjuvant setting and collected cryopreserved tumor samples before and after treatment." | 9.14 | Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. ( Brady, MS; Carvajal, RD; Chapman, PB; Coit, DG; Gold, JS; Panageas, KS; Shah, GD; Socci, ND; Viale, A; Wolchok, JD, 2010) |
| "The combination of temozolomide (TMZ) and thalidomide was reported to produce a high response rate, including shrinkage of brain metastases, in patients with metastatic melanoma." | 9.13 | Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008) |
| "Temozolomide and fotemustine are both active drugs for treating metastatic melanoma." | 9.13 | Temozolomide in combination with fotemustine in patients with metastatic melanoma. ( Camlica, H; Tas, F; Topuz, E, 2008) |
| "We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma." | 9.13 | Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. ( Bael, TE; Gollob, JA; Peterson, BL, 2008) |
| "We conducted a phase II trial of extended-dose temozolomide (TMZ) in patients with melanoma to test the hypothesis that the approximately 30% response rate observed in patients treated with extended-dose TMZ with antiangiogenic agents was caused by TMZ alone." | 9.13 | Phase II study of extended-dose temozolomide in patients with melanoma. ( Busam, K; Chapman, PB; Gerst, S; Jungbluth, AA; Krown, S; Orlow, I; Panageas, K; Rietschel, P; Smith, K; Wolchok, JD, 2008) |
| "Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases." | 9.12 | A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. ( Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S, 2006) |
| "Temozolomide and interferon-alpha-2b (IFN-alpha-2b) are both active in melanoma." | 9.12 | Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. ( Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD, 2006) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 9.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "Temozolomide is a novel oral alkylating agent, active against metastatic melanoma." | 9.12 | Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. ( Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M, 2006) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 9.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours." | 9.12 | Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. ( Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T, 2006) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 9.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma." | 9.12 | Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. ( Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ, 2007) |
| "A multicentre, centrally randomized, open-labelled study with temozolomide and interferon (IFN)-alpha 2b was carried out to study the therapeutic effect in patients with metastatic melanoma stage IV." | 9.11 | Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. ( Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B, 2004) |
| "Temozolomide (TMZ) is a new oral alkylating agent which has proven to be as active as dacarbazine (DTIC) in the treatment of melanoma, but with a lower toxicity." | 9.11 | Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. ( Amaducci, L; Biasco, G; Guida, M; Leoni, M; Michiara, M; Poletti, P; Ravaioli, A; Ridolfi, R; Romanini, A; Sileni, VC, 2004) |
| "Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma." | 9.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 9.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
| "Temozolomide (TMZ) has shown efficacy in metastatic melanoma equal to that of dacarbazine (DTIC), the standard chemotherapeutic agent for melanoma." | 9.11 | Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. ( Becker, JC; Dummer, R; Garbe, C; Kaufmann, R; Krengel, S; Kretschmer, L; Leiter, U; Linse, R; Mauch, C; Schadendorf, D; Sebastian, G; Spieth, K; Tilgen, W; Vogt, T; von den Driesch, P, 2005) |
| "The present study was designed to assess the efficacy and safety of combination therapy with temozolomide plus cisplatin in patients with metastatic melanoma." | 9.11 | Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. ( Argon, A; Camlica, H; Tas, F; Topuz, E, 2005) |
| "In an effort to reduce the frequency of central nervous system (CNS) progression in patients with metastatic melanoma with ongoing systemic response to biochemotherapy, we modified our standard concurrent biochemotherapy regimen by replacing dacarbazine (DTIC) with oral temozolomide." | 9.10 | A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. ( Atkins, MB; Gollob, JA; McDermott, DF; Mier, JW; Parker, RA; Sorokin, P; Sosman, JA; Tutin, L, 2002) |
| "Temozolomide (Temodar) has demonstrated clinical activity against melanoma equivalent to that of intravenous dacarbazine (DTIC)." | 9.10 | Phase II evaluation of temozolomide in metastatic choroidal melanoma. ( Bedikian, AY; Eton, O; Papadopoulos, N; Plager, C; Ring, S, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases." | 9.10 | Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003) |
| "Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activity in patients with advanced melanoma." | 9.10 | A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. ( Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ, 2003) |
| "Temozolomide is a novel oral alkylating agent that is effective against melanoma." | 9.10 | Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 9.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain." | 9.10 | Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. ( Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002) |
| "To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma." | 9.10 | Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Livingston, PO; Menell, JH; Panageas, KS; Quinn, CJ; Williams, LJ, 2002) |
| "To determine the potential economic implications resulting from oral temozolomide (TEM) compared with intravenous (IV) dacarbazine (DTIC) for metastatic melanoma." | 9.09 | Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. ( Agarwala, S; Hillner, BE; Middleton, MR, 2000) |
| "Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use." | 9.08 | Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995) |
| " In a clinical trial of temozolomide in advanced malignant melanoma, the relationship between pretreatment MGMT levels in biopsies of cutaneous tumours and involved lymph nodes and clinical response to the drug has been studied." | 9.08 | O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. ( Bleehen, NM; Brampton, MH; Calvert, AH; Lee, SM; Lind, MJ; Lunn, JM; Margison, GP; Middleton, MR; Morris, C; Newell, DR; Newlands, ES; Rustin, G; Thatcher, N; Wedge, SR, 1998) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 8.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "Temozolomide (TMZ) has received much attention, notably in the treatment of malignant glioma and malignant melanoma." | 8.90 | Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis. ( Jia, HY; Jiang, G; Lei, TC; Li, RH; Liu, YQ; Sun, C, 2014) |
| " Two chemotherapeutic regimens are commonly used for the palliative treatment of malignant melanoma: intravenous administration of single-agent dacarbazine or oral administration of temozolomide." | 8.89 | Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. ( Abdollahi, M; Nikfar, S; Teimouri, F, 2013) |
| "Patients with brain metastasis were identified from 3 prospective studies of temozolomide (with or without immunotherapy) for metastatic melanoma." | 8.84 | Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? ( Boogerd, W; Dalesio, O; de Gast, GC, 2007) |
| "This systematic review examines the role of temozolomide in patients with metastatic melanoma." | 8.84 | Temozolomide for the treatment of metastatic melanoma: a systematic review. ( Bak, K; Charette, M; Petrella, T; Quirt, I; Verma, S, 2007) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 8.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "Cutaneous melanomas frequently metastasize to the brain, with temozolomide (TMZ) plus radiotherapy (RT) offering little control of these lesions." | 7.91 | Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: A role for autophagy and premature senescence. ( Allavena, G; Del Bello, B; Maellaro, E; Miracco, C; Pirtoli, L; Tini, P; Valacchi, G; Volpi, N, 2019) |
| "To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma." | 7.88 | Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. ( Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D, 2018) |
| "Temozolomide (TMZ) is widely used to treat melanoma; however, response rates to TMZ are low because of rapid and frequent resistance." | 7.88 | Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma. ( Feng, S; Guo, W; Huang, Q; Jiang, A; Jiang, G; Liu, Y; Tang, J; Tao, Y; Xu, X; Yang, C; Yang, M, 2018) |
| "Since temozolomide (TMZ) is activated under alkaline conditions, we expected lonidamine (LND) to have no effect or perhaps diminish its activity, but initial results suggest it may actually enhance either or both short- and long-term activity of TMZ in melanoma xenografts." | 7.85 | Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide. ( Glickson, JD; Lee, SC; Leeper, DB; Nath, K; Nelson, DS; Putt, ME; Roman, J, 2017) |
| "The present study was carried out to prepare and evaluate a temozolomide (TMZ)-loaded polyamide-amine dendrimer (PAMAM)‑based nanodrug delivery system, and to explore its ability to target human melanoma (A375) cells in vitro." | 7.85 | Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells. ( Guo, W; Hou, X; Jiang, G; Li, R; Liu, Y; Ma, Y; Tang, J; Xin, Y; Yang, C, 2017) |
| "This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m(2) on days 1-7 and 15-21) in 36 patients with metastatic uveal melanoma (MUM)." | 7.83 | Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. ( Asselain, B; Bidard, FC; Cassoux, N; Decaudin, D; Diallo, A; Etienne-Grimaldi, MC; Mariani, P; Piperno-Neumann, S; Plancher, C; Rodrigues, M; Servois, V, 2016) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 7.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "The aim of this study was to investigate the effect of Ki67-ZD55-IL-24 with temozolomide (TMZ) against melanoma in mice." | 7.81 | Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo. ( Jiang, G; Li, RH; Liu, YQ; Sun, C; Wei, ZP; Zheng, JN, 2015) |
| "To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed." | 7.81 | MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. ( Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P, 2015) |
| "The alkylating agent temozolomide (TMZ) represents an important component of current melanoma therapy, but overexpression of O6-methyl-guanine DNA methyltransferase (MGMT) in tumor cells confers resistance to TMZ and impairs therapeutic outcome." | 7.81 | A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. ( Chen, TC; Cho, HY; Hofman, FM; Jhaveri, N; Nguyen, J; Rosenstein-Sisson, R; Schönthal, AH; Wang, W, 2015) |
| "Melanoma exhibits variable resistance to the alkylating agent temozolomide (TMZ)." | 7.80 | Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide. ( Egger, ME; Gomez-Gutierrez, JG; McMasters, KM; McNally, LR; Nitz, J, 2014) |
| " On the basis of this, we conducted a study on DC-based vaccination in advanced melanoma, adding low-dose temozolomide to obtain lymphodepletion." | 7.79 | Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. ( Ancarani, V; Ascierto, PA; Baravelli, S; de Rosa, F; Fiammenghi, L; Gentilcore, G; Granato, AM; Guidoboni, M; Nicoletti, SV; Pancisi, E; Petrini, M; Riccobon, A; Ridolfi, L; Ridolfi, R; Scarpi, E; Simeone, E; Valmorri, L, 2013) |
| "The major cytotoxic DNA adduct induced by temozolomide and other methylating agents used in malignant glioma and metastasized melanoma therapy is O(6)-methylguanine (O(6)-MeG)." | 7.79 | Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. ( Eich, M; Kaina, B; Nikolova, T; Roos, WP, 2013) |
| "Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism." | 7.79 | XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. ( Byron, SA; Doudican, NA; Orlow, SJ; Pollock, PM, 2013) |
| "First line treatment of metastatic melanoma includes the methylating agent dacarbazine or its analogue temozolomide (TMZ) with improved pharmacokinetics and tolerability." | 7.77 | The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. ( Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P, 2011) |
| "The efficacy of temozolomide in melanoma treatment is low (response rate <20%) and may depend on the activity of O-methylguanine DNA methyltransferase (MGMT) and mismatch repair." | 7.77 | Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. ( Boeckmann, L; Emmert, S; Kuschal, C; Nickel, AC; Schaefer, A; Schön, MP; Thomale, J; Thoms, KM, 2011) |
| " Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases." | 7.77 | Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. ( Chen, R; Devito, N; Pan, E; Yu, M, 2011) |
| "This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma." | 7.76 | Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? ( Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE, 2010) |
| "All patients with metastatic melanoma treated with either dacarbazine (DTIC) or temozolomide (TMZ) at the British Columbia Cancer Agency (BCCA) from January 1, 1988 to February 1, 2006 were identified through the BCCA pharmacy electronic database, which was then linked to the surveillance and outcomes unit to identify patients with LTS, defined as survival > or =18 months following chemotherapy." | 7.76 | Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. ( Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A, 2010) |
| "The alkylating agent dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved." | 7.76 | Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. ( Burd, R; Limesand, KH; Mendoza, EE; Mitchell, GC; Radhakrishnan, VM; Sittadjody, S; Thangasamy, T, 2010) |
| "Despite limited clinical efficacy, treatment with dacarbazine or temozolomide (TMZ) remains the standard therapy for metastatic melanoma." | 7.76 | MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. ( Dummer, R; Edler, L; Hassel, JC; Kurzen, H; Mauch, C; Moll, I; Rass, K; Schadendorf, D; Spieth, K; Stresemann, C; Sucker, A, 2010) |
| "Despite objective response rates of only approximately 13%, temozolomide remains one of the most effective single chemotherapy agents against metastatic melanoma, second only to dacarbazine, the current standard of care for systemic treatment of melanoma." | 7.75 | Genomic and molecular profiling predicts response to temozolomide in melanoma. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Nevins, JR; Potti, A; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2009) |
| " A 67-year-old renal transplant recipient developed a nodular malignant melanoma after 30 years of immunosuppression with azathioprine and prednisolone." | 7.75 | Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. ( Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F, 2009) |
| "The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair." | 7.75 | Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians. ( Boeckmann, L; Brockmoeller, J; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Rosenberger, A; Schirmer, M; Schoen, MP; Struever, D; Thoms, KM, 2009) |
| "Efforts to improve melanoma response rates to temozolomide (TMZ) have thus far been unsuccessful." | 7.75 | Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. ( Chen, M; Doudican, N; Orlow, SJ; Osman, I; Rose, AE, 2009) |
| "Dasatinib has both anti-proliferative and anti-invasive effects in melanoma cells and combined with chemotherapy may have clinical benefit in the treatment of malignant melanoma." | 7.74 | Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. ( Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N, 2008) |
| "Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O(6)-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response." | 7.74 | Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2007) |
| "Temozolomide (TMZ), a DNA alkylating agent used in the treatment of melanoma, is believed to mediate its effect by addition of a methyl group to the O(6) position of guanine in DNA." | 7.74 | Temozolomide induces senescence but not apoptosis in human melanoma cells. ( Allen, J; Avery-Kiejda, KA; Hersey, P; Mhaidat, NM; Scott, RJ; Zhang, XD, 2007) |
| "Temozolomide is an oral alkylating agent used in the treatment of metastatic melanoma." | 7.74 | Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. ( Neff, WJ; Nystrom, KK; Pick, AM, 2008) |
| " In this study, cilengitide was tested in combination with the methylating agent temozolomide (TMZ), a well-tolerated anticancer drug with favourable pharmacokinetic properties currently used for the therapy of metastatic melanoma." | 7.74 | The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. ( Dorio, AS; Graziani, G; Lacal, PM; Muzi, A; Navarra, P; Ruffini, F; Tentori, L, 2008) |
| "The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma." | 7.73 | Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M, 2006) |
| "This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT)." | 7.73 | Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. ( Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y, 2006) |
| " Aim of the present study was to investigate the molecular mechanisms underlying acquired resistance of melanoma cells to TMZ and the effect of O6-benzylguanine (BG), a specific MGMT inhibitor, on the development of a TMZ-resistant phenotype." | 7.73 | A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. ( Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G, 2006) |
| "In the present study, we have investigated the influence of telomerase inhibition in chemosensitivity of melanoma cells to temozolomide (TMZ), a methylating agent with promising antitumor activity against metastatic melanoma." | 7.72 | Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. ( Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M, 2003) |
| "Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine." | 7.72 | Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004) |
| "Ten patients with malignant melanoma and phototoxic reactions under dacarbazine or 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) chemotherapy were investigated." | 7.72 | Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. ( Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R, 2004) |
| "The present observation suggests that temozolomide may be an active and well tolerated treatment for malignant melanoma brain metastases." | 7.72 | Complete response of multiple melanoma brain metastases after treatment with temozolomide. ( Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J, 2004) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 7.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 7.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "2 mg/kg three times weekly for 2 weeks (starting on day 1), in combination with oral panobinostat 10, 20, or 30 mg every 96 h (starting on day 8), and oral temozolomide 150 mg/m(2)/day on days 9 through 13." | 6.79 | Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). ( Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014) |
| "Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies." | 6.74 | A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009) |
| " Accordingly, a clinical trial using oral temozolomide (TMZ) and subcutaneous PEG-interferon alpha-2b (PEG) in patients with metastatic melanoma was designed to determine the maximal tolerated dosage of both drugs and the antitumoral response." | 6.73 | Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. ( Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC, 2008) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 6.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration." | 6.72 | Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006) |
| " Therefore, the authors initiated a Phase I study to determine the pharmacokinetics and safety profile of temozolomide (TMZ), a novel oral alkylating agent known to cross the blood-brain barrier, in combination with interferon alpha-2b (IFN-alpha2b)." | 6.71 | Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. ( Agarwala, SS; Kirkwood, JM, 2003) |
| "Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS." | 6.71 | Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. ( Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N, 2004) |
| "Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%." | 6.71 | The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. ( Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D, 2004) |
| "Temozolomide (TMZ) is an oral alkylating agent that produces methyl adducts at the 0." | 6.71 | Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Chalkidou, S; Christodoulou, C; Efstathiou, E; Fountzilas, G; Gogas, H; Iconomou, T; Kalofonos, H; Kouroussis, C; Linardou, E; Panagiotou, P; Polyzos, A; Tsoutsos, D, 2005) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 6.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| " The absolute bioavailability of TMZ was 0." | 6.69 | Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ( Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F, 1998) |
| "nab-Paclitaxel has single agent activity in chemotherapy-naïve untreated metastatic melanoma which compares favorably to the activity of weekly paclitaxel or single agent dacarbazine." | 6.61 | Efficacy of nab-paclitaxel in treating metastatic melanoma. ( Specenier, P, 2019) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 6.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Melanoma is a tumour derived from melanocytes, cells of neuroectodermal origin." | 6.47 | [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities]. ( Czyż, M; Koprowska, K, 2011) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 6.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 6.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| "Temozolomide (TMZ) is a chemotherapy agent used to treat primary central nervous system tumors." | 5.91 | Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis. ( Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F, 2023) |
| "To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma." | 5.69 | Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. ( Bai, X; Cheng, F; Chi, Z; Cui, C; Dai, J; Duan, R; Guo, J; Kong, Y; Li, C; Li, J; Li, S; Lian, B; Mao, L; Pang, Z; Sheng, X; Si, L; Tang, B; Wang, X; Wei, X; Wu, X; Xia, F; Xu, H; Yan, X; Yang, Y; Zhang, C; Zhou, L, 2023) |
| "Temozolomide was administered orally once per day at a dosage of 200 mg/m2/d for five consecutive days about every 4 weeks." | 5.56 | Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. ( Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X, 2020) |
| "A novel core‑shell type thermo‑nanoparticle (CSTNP) co‑loaded with temozolomide (TMZ) and the fluorescein new indocyanine green dye IR820 (termed IT‑CSTNPs) was designed and combined with a near‑infrared (NIR) laser to realize its photothermal conversion." | 5.51 | Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells. ( Hou, X; Jiang, G; Li, X; Liu, W; Liu, Y; Pang, Y; Yang, C, 2019) |
| "Malignant melanoma is a highly aggressive skin cancer that is highly resistant to chemotherapy." | 5.51 | Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy. ( Aizawa, S; Hara, H; Harada, T; Makita, K; Nakayama, T; Ochiai, Y; Okamoto, Y; Sano, E; Ueda, T; Yoshino, A, 2019) |
| "The incidence of malignant melanoma is increasing." | 5.48 | Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment. ( Abramov, I; Khochenkov, D; Prokofieva, A; Ryabaya, O; Stepanova, E; Zasedatelev, A, 2018) |
| "One of the most common treatments for melanoma is surgery, followed by various combinations of chemotherapy drugs." | 5.46 | Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism. ( Chang, X; Lian, S; Zhang, H; Zhu, W, 2017) |
| "Malignant melanoma is an aggressive, highly lethal dermatological malignancy." | 5.43 | DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines. ( Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M, 2016) |
| " The present study used a patient-derived orthotopic xenograft (PDOX) nude-mouse model of melanoma with a BRAF-V600E mutation to determine the efficacy of temozolomide (TEM) combined with tumor-targeting Salmonella typhimurium A1-R." | 5.43 | Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. ( Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, A; Unno, M; Zhang, Y; Zhao, M, 2016) |
| "Malignant melanoma is one of the most lethal and aggressive human malignancies." | 5.39 | A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. ( Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Tian, H; Zheng, JN, 2013) |
| "Metastatic melanoma has poor prognosis and is refractory to most conventional chemotherapies." | 5.37 | The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. ( Cooper, DA; Fujita, M; Goldstein, NB; Norris, DA; Partyka, KA; Reuland, SN; Shellman, YG, 2011) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 5.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| " Drug combination of TMZ plus BG and PHA-848125 produced additive or synergistic effects on cell growth, depending on the cell line." | 5.36 | The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. ( Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G, 2010) |
| "Uveal melanoma is refractory to chemotherapy." | 5.35 | Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. ( Aldrich, W; Dombos, C; Triozzi, PL, 2008) |
| "Melanoma is the most malignant of skin cancers, highly resistant to chemotherapy and radiotherapy." | 5.35 | Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. ( Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M, 2008) |
| "Malignant melanomas are highly resistant to chemotherapy." | 5.35 | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009) |
| "Temozolomide (TMZ) is a methylating agent that spontaneously decomposes into the active metabolite of dacarbazine, the most effective agent for the systemic treatment of melanoma." | 5.34 | Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity. ( Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M, 2007) |
| "Indeed melanomas have proven resistant to apoptosis (type I programmed cell death (PCD)) and consequently to most chemotherapy and immunotherapy." | 5.34 | Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. ( De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S, 2007) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 5.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| "Temozolomide (TMZ) has shown efficacy in the treatment of metastatic melanoma." | 5.33 | Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. ( Castel, T; Conill, C; Domingo-Doménech, J; Gallego, R; Jorcano, S; Malvehy, J; Puig, S; Sánchez, M; Vilella, R, 2006) |
| "Temozolomide (TMZ) displays efficacy for the treatment of metastatic melanoma." | 5.32 | [Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation]. ( Castel, T; Conill, C; Fernández-Ibiza, J; Malvehy, J; Puig, S; Sánchez, M, 2004) |
| "Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease." | 5.32 | In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004) |
| " The aim of this phase I study was to determine the maximum tolerated dose of the combination of TPI 287 and temozolomide in metastatic melanoma." | 5.22 | A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. ( Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP, 2016) |
| "Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaires were collected from subjects enrolled a phase I ILI trial with temozolomide at baseline and 2, 6 weeks, and 3 months post-ILI." | 5.20 | Quality of life after isolated limb infusion for in-transit melanoma of the extremity. ( Abernethy, AP; Jiang, BS; Mosca, PJ; Speicher, PJ; Thomas, S; Tyler, DS, 2015) |
| "In this multicenter, double-blind trial, adults with unresectable stage III or IV metastatic melanoma were randomized 1:1:1 to TMZ plus veliparib 20 or 40 mg, or placebo twice daily." | 5.20 | Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. ( Chyla, B; Daud, A; Falotico, N; Friedlander, P; Giranda, VL; Hamid, O; Jiang, F; Luo, Y; McArthur, GA; McKee, M; McKeegan, E; Middleton, MR; Mostafa, NM; Plummer, R; Qian, J; Zhu, M, 2015) |
| "In this phase 1b study, patients with stage 4 or unresectable stage 3 melanoma were treated with escalating doses of lenvatinib (once daily) and temozolomide (TMZ) (days 1-5) in 28-day cycles, to determine the maximum tolerated dose (MTD) of the combination." | 5.20 | Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. ( Andresen, C; Falchook, GS; George, GC; Hong, DS; Kim, KB; Kurzrock, R; Kwak, J; Nemunaitis, J; Nguyen, LM; O'Brien, JP; Ren, M; Xu, L, 2015) |
| "We conducted a single-arm phase II multi-institution cooperative group study to assess the antitumor activity and safety profile of the combination of TMZ and the rapamycin derivative everolimus in patients with metastatic unresectable malignant melanoma." | 5.19 | Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. ( Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M, 2014) |
| "This study showed that temozolomide (150-200 mg/m(2)/day) can safely be given with a PARP inhibitory dose of rucaparib, increasing progression-free survival over historical controls in metastatic melanoma patients." | 5.17 | A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. ( Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH, 2013) |
| "Patients with mucosal melanoma in stage II/III after surgery were randomized into three groups: observation group (group A, surgery alone), HDI group (group B, treated with 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 × 10(6) U IFN-α2b), and temozolomide (200 mg/m(2)/d) plus cisplatin (75 mg/m(2)) group (group C)." | 5.17 | Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. ( Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B, 2013) |
| "The combination of oblimersen, temozolomide, and nab-paclitaxel was well tolerated and demonstrated encouraging activity in patients with advanced melanoma." | 5.17 | Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. ( Chang, J; Cheng, X; Escano, C; Gandhi, A; Kannan, R; Liebes, L; Madden, K; Mendoza, S; Muren, C; Ott, PA; Pavlick, AC; Shao, Y, 2013) |
| "Temozolomide (TMZ) is widely used for chemotherapy of metastatic melanoma." | 5.17 | Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. ( Beumer, JH; Buch, SC; Christner, S; Egorin, MJ; Kirkwood, JM; Lin, Y; Moschos, S; Tarhini, AA; Tawbi, HA, 2013) |
| "Previously untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10 mg/kg body weight i." | 5.16 | First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). ( Cathomas, R; Dummer, R; Gillessen, S; Goldinger, SM; Mamot, C; Michielin, O; Mjhic-Probst, D; Moch, H; Ochsenbein, A; Schläppi, M; Schönewolf, N; Schraml, PH; Seifert, B; Simcock, M; von Moos, R, 2012) |
| "To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma." | 5.16 | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. ( Bastholt, L; Cantarini, M; Dummer, R; Hersey, P; Kemsley, K; Kirkwood, JM; Larkin, J; Middleton, M; Robert, C; Sosman, J; Zazulina, V, 2012) |
| "The study is a proof-of-principle trial evaluating toxicity, immune response, and clinical response in melanoma patients after combined therapy with temozolomide and the telomerase peptide vaccine GV1001." | 5.15 | Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. ( Aamdal, S; Dueland, S; Gaudernack, G; Julsrud, L; Kyte, JA; Trachsel, S, 2011) |
| "To compare the efficacy of an extended schedule escalated dose of temozolomide versus standard dose dacarbazine in a large population of patients with stage IV melanoma." | 5.15 | Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). ( Agarwala, SS; Becker, J; Conry, R; Davidson, N; Dummer, R; Eggermont, AM; Engelen, K; Hwu, WJ; Keilholz, U; Kruit, WH; Mortier, L; Patel, PM; Punt, CJ; Robert, C; Schadendorf, D; Spatz, A; Suciu, S; Thompson, JA; Trefzer, U, 2011) |
| "This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients." | 5.15 | Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. ( Brugnara, S; Chiarion-Sileni, V; Colucci, G; De Salvo, GL; Del Bianco, P; Guida, M; Pigozzo, J; Ridolfi, L; Ridolfi, R; Romanini, A, 2011) |
| "In a search for more effective combination chemotherapy for the treatment of metastatic melanoma, we conducted a phase I trial of a novel combination of docetaxel, temozolomide, and cisplatin." | 5.14 | Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. ( Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE, 2009) |
| "We evaluated the pharmacodynamic effects of the O(6)-methylguanine-DNA methyltransferase (MGMT) inactivator lomeguatrib (LM) on patients with melanoma in two clinical trials." | 5.14 | O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. ( Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ, 2009) |
| "This alternating weekly, dose-dense temozolomide regimen was well tolerated and clinically active in heavily pretreated patients with brain metastases, particularly in patients with melanoma." | 5.14 | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. ( Bajetta, E; Cascinu, S; Crinò, L; Danova, M; Del Prete, S; Salvagni, S; Schiavetto, I; Siena, S; Vitali, M, 2010) |
| "Patients must have had stage IV cutaneous melanoma, no active brain metastases, Zubrod PS 0-1, up to 1 prior systemic therapy excluding thalidomide, temozolomide, or dacarbazine, adequate organ function, and given informed consent." | 5.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "Preclinical studies show that bortezomib, a proteasome inhibitor, blocks NF-kappaB activation and, combined with temozolomide, enhances activity against human melanoma xenografts and modulates other critical tumor targets." | 5.14 | A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. ( Amiri, KI; Ayers, GD; Horton, LW; Kelley, MC; Koehler, E; Puzanov, I; Richmond, A; Sosman, JA; Su, Y; Yu, Y, 2010) |
| "Temozolomide (TMZ) is a second-generation alkylating agent that has recently shown some efficacy in stage IV melanoma." | 5.14 | Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial. ( Bedane, C; Guillet, G; Guillot, B; Mourey, L; Sassolas, B; Tourani, JM; Wierzbicka-Hainaut, E, 2010) |
| "We treated melanoma patients with temozolomide (TMZ) in the neoadjuvant setting and collected cryopreserved tumor samples before and after treatment." | 5.14 | Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. ( Brady, MS; Carvajal, RD; Chapman, PB; Coit, DG; Gold, JS; Panageas, KS; Shah, GD; Socci, ND; Viale, A; Wolchok, JD, 2010) |
| "The combination of temozolomide (TMZ) and thalidomide was reported to produce a high response rate, including shrinkage of brain metastases, in patients with metastatic melanoma." | 5.13 | Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008) |
| "Temozolomide and fotemustine are both active drugs for treating metastatic melanoma." | 5.13 | Temozolomide in combination with fotemustine in patients with metastatic melanoma. ( Camlica, H; Tas, F; Topuz, E, 2008) |
| "We conducted a single institution phase II trial to evaluate the tolerability and effectiveness of therapy with arsenic trioxide (ATO) and ascorbic acid (AA) with temozolomide (TMZ) in patients with advanced melanoma." | 5.13 | Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. ( Bael, TE; Gollob, JA; Peterson, BL, 2008) |
| "We conducted a phase II trial of extended-dose temozolomide (TMZ) in patients with melanoma to test the hypothesis that the approximately 30% response rate observed in patients treated with extended-dose TMZ with antiangiogenic agents was caused by TMZ alone." | 5.13 | Phase II study of extended-dose temozolomide in patients with melanoma. ( Busam, K; Chapman, PB; Gerst, S; Jungbluth, AA; Krown, S; Orlow, I; Panageas, K; Rietschel, P; Smith, K; Wolchok, JD, 2008) |
| "Our objective was to evaluate the toxicity and antitumor efficacy of concurrent biochemotherapy in metastatic melanoma patients and the effectiveness of adding temozolomide to protect the brain from metastases." | 5.12 | A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study. ( Asna, N; Inbar, MJ; Metser, U; Ron, IG; Ryvo, L; Safra, T; Sapir, EE; Sarid, D; Schneebaum, S, 2006) |
| "Temozolomide and interferon-alpha-2b (IFN-alpha-2b) are both active in melanoma." | 5.12 | Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. ( Aird, S; Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Panageas, KS; Williams, LJ; Wolchok, JD, 2006) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 5.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "Temozolomide is a novel oral alkylating agent, active against metastatic melanoma." | 5.12 | Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma. ( Crespo, C; del Muro, XG; Filipovich, E; García, M; Germà-Lluch, JR; López, JJ; Pérez, X; Rifà, J; Tres, A; Valladares, M, 2006) |
| "The combination of TMZ and celecoxib is safe and potentially effective in the treatment of metastatic melanoma." | 5.12 | Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. ( Fountzilas, G; Frangia, K; Gogas, H; Mantzourani, M; Markopoulos, C; Middleton, M; Panagiotou, P; Papadopoulos, O; Pectasides, D; Polyzos, A; Stavrinidis, I; Tsoutsos, D; Vaiopoulos, G, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Temozolomide has shown some efficacy in metastatic melanoma and recently received extended approval to treat brain tumours." | 5.12 | Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. ( Egberts, F; Garbe, C; Hauschild, A; Kreissig, M; Linse, R; Mohr, P; Schadendorf, D; Thoelke, A; Tilgen, W; Trefzer, U; Ugurel, S; Vogt, T, 2006) |
| "Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain." | 5.12 | A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007) |
| "To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma." | 5.12 | Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. ( Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ, 2007) |
| "A multicentre, centrally randomized, open-labelled study with temozolomide and interferon (IFN)-alpha 2b was carried out to study the therapeutic effect in patients with metastatic melanoma stage IV." | 5.11 | Temozolomide and interferon alpha 2b in metastatic melanoma stage IV. ( Fialla, R; Forstinger, Ch; Fritsch, P; Hofmann-Wellenhof, R; Kehrer, H; Kerl, H; Kindermann-Glebowski, E; Klein, G; Koller, J; Konrad, K; Kos, C; Lang, A; Mischer, P; Pachinger, W; Pehamberger, H; Raml, J; Ratzinger, G; Richtig, E; Seeber, A; Smolle, J; Steiner, A; Ulmer, H; Wolff, K; Zelger, B, 2004) |
| "Temozolomide (TMZ) is a new oral alkylating agent which has proven to be as active as dacarbazine (DTIC) in the treatment of melanoma, but with a lower toxicity." | 5.11 | Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. ( Amaducci, L; Biasco, G; Guida, M; Leoni, M; Michiara, M; Poletti, P; Ravaioli, A; Ridolfi, R; Romanini, A; Sileni, VC, 2004) |
| "Temozolomide plus thalidomide was an active oral regimen for patients with brain metastases from malignant melanoma." | 5.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "Temozolomide (200 mg/m2 oral administration) was given to 12 patients with metastatic malignant melanoma." | 5.11 | Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. ( Boddy, AV; Calvert, AH; Curtin, NJ; Harris, AL; Hickson, I; Jones, C; Margison, GP; McGown, G; McHugh, P; Middleton, MR; Newell, DR; Olsen, A; Plummer, ER; Thorncroft, M; Watson, AJ, 2005) |
| "Temozolomide (TMZ) has shown efficacy in metastatic melanoma equal to that of dacarbazine (DTIC), the standard chemotherapeutic agent for melanoma." | 5.11 | Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. ( Becker, JC; Dummer, R; Garbe, C; Kaufmann, R; Krengel, S; Kretschmer, L; Leiter, U; Linse, R; Mauch, C; Schadendorf, D; Sebastian, G; Spieth, K; Tilgen, W; Vogt, T; von den Driesch, P, 2005) |
| "The present study was designed to assess the efficacy and safety of combination therapy with temozolomide plus cisplatin in patients with metastatic melanoma." | 5.11 | Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. ( Argon, A; Camlica, H; Tas, F; Topuz, E, 2005) |
| "In an effort to reduce the frequency of central nervous system (CNS) progression in patients with metastatic melanoma with ongoing systemic response to biochemotherapy, we modified our standard concurrent biochemotherapy regimen by replacing dacarbazine (DTIC) with oral temozolomide." | 5.10 | A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. ( Atkins, MB; Gollob, JA; McDermott, DF; Mier, JW; Parker, RA; Sorokin, P; Sosman, JA; Tutin, L, 2002) |
| "Temozolomide (Temodar) has demonstrated clinical activity against melanoma equivalent to that of intravenous dacarbazine (DTIC)." | 5.10 | Phase II evaluation of temozolomide in metastatic choroidal melanoma. ( Bedikian, AY; Eton, O; Papadopoulos, N; Plager, C; Ring, S, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases." | 5.10 | Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003) |
| "Temozolomide is an oral alkylating agent that readily crosses the blood-brain barrier and has activity in patients with advanced melanoma." | 5.10 | A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma. ( Boxall, J; Marples, M; Meyer, T; Napier, MP; Rustin, GJ; Strauss, SJ, 2003) |
| "Temozolomide is a novel oral alkylating agent that is effective against melanoma." | 5.10 | Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D, 2002) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 5.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To evaluate the antitumor effects and toxicities of whole brain irradiation (WBI) with temozolomide (TMZ) administered by prolonged oral dosing in patients with melanoma metastatic to the brain." | 5.10 | Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. ( Atkins, B; Clark, I; Dutcher, P; Ernstoff, S; Flaherty, L; Gollob, J; II Smith, W; Johnson, D; Longmate, J; Margolin, K; Sosman, J; Thompson, A; Weber, J; Weiss, G, 2002) |
| "To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma." | 5.10 | Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Livingston, PO; Menell, JH; Panageas, KS; Quinn, CJ; Williams, LJ, 2002) |
| "To determine the potential economic implications resulting from oral temozolomide (TEM) compared with intravenous (IV) dacarbazine (DTIC) for metastatic melanoma." | 5.09 | Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma. ( Agarwala, S; Hillner, BE; Middleton, MR, 2000) |
| "Temozolomide in the schedule used has as good activity in chemotherapy-naive metastatic melanoma as the other most active agents currently in use." | 5.08 | Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. ( Bleehen, NM; Brampton, M; Calvert, AH; Lee, SM; Newlands, ES; Rustin, GJ; Selby, P; Stevens, MF; Thatcher, N, 1995) |
| " In a clinical trial of temozolomide in advanced malignant melanoma, the relationship between pretreatment MGMT levels in biopsies of cutaneous tumours and involved lymph nodes and clinical response to the drug has been studied." | 5.08 | O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. ( Bleehen, NM; Brampton, MH; Calvert, AH; Lee, SM; Lind, MJ; Lunn, JM; Margison, GP; Middleton, MR; Morris, C; Newell, DR; Newlands, ES; Rustin, G; Thatcher, N; Wedge, SR, 1998) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 4.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "Temozolomide (TMZ) has received much attention, notably in the treatment of malignant glioma and malignant melanoma." | 4.90 | Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis. ( Jia, HY; Jiang, G; Lei, TC; Li, RH; Liu, YQ; Sun, C, 2014) |
| "Before 2011, dacarbazine and IL-2 were the only FDA approved therapies for metastatic melanoma, and IFN-α is the only approved agent for adjuvant therapy." | 4.90 | Current systemic therapies for melanoma. ( Bordeaux, JS; Koon, HB; Palathinkal, DM; Sharma, TR, 2014) |
| " Two chemotherapeutic regimens are commonly used for the palliative treatment of malignant melanoma: intravenous administration of single-agent dacarbazine or oral administration of temozolomide." | 4.89 | Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. ( Abdollahi, M; Nikfar, S; Teimouri, F, 2013) |
| "Temozolomide is an oral alkylating agent with established antitumor activity in patients with primary brain tumors and melanoma." | 4.86 | Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. ( Hwu, WJ; Neyns, B; Reardon, DA; Tosoni, A, 2010) |
| "Patients with brain metastasis were identified from 3 prospective studies of temozolomide (with or without immunotherapy) for metastatic melanoma." | 4.84 | Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? ( Boogerd, W; Dalesio, O; de Gast, GC, 2007) |
| "This systematic review examines the role of temozolomide in patients with metastatic melanoma." | 4.84 | Temozolomide for the treatment of metastatic melanoma: a systematic review. ( Bak, K; Charette, M; Petrella, T; Quirt, I; Verma, S, 2007) |
| "Temozolomide plays a role in treating melanoma refractory to immunomodulatory and mitogen-activated protein kinase-targeted approaches, but its efficacy is limited." | 4.31 | Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma. ( Benes, EN; Friedlander, P; Jursic, B; Morgan, LR; Rodgers, AH, 2023) |
| "To our knowledge, there are minimal reports of temozolomide-induced DRESS syndrome." | 4.12 | Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy. ( Ambur, A; Ambur, L; Khan, L; Nathoo, R, 2022) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 4.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "Cutaneous melanomas frequently metastasize to the brain, with temozolomide (TMZ) plus radiotherapy (RT) offering little control of these lesions." | 3.91 | Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: A role for autophagy and premature senescence. ( Allavena, G; Del Bello, B; Maellaro, E; Miracco, C; Pirtoli, L; Tini, P; Valacchi, G; Volpi, N, 2019) |
| "To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma." | 3.88 | Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. ( Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D, 2018) |
| "Temozolomide (TMZ) is widely used to treat melanoma; however, response rates to TMZ are low because of rapid and frequent resistance." | 3.88 | Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma. ( Feng, S; Guo, W; Huang, Q; Jiang, A; Jiang, G; Liu, Y; Tang, J; Tao, Y; Xu, X; Yang, C; Yang, M, 2018) |
| "Since temozolomide (TMZ) is activated under alkaline conditions, we expected lonidamine (LND) to have no effect or perhaps diminish its activity, but initial results suggest it may actually enhance either or both short- and long-term activity of TMZ in melanoma xenografts." | 3.85 | Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide. ( Glickson, JD; Lee, SC; Leeper, DB; Nath, K; Nelson, DS; Putt, ME; Roman, J, 2017) |
| "The present study was carried out to prepare and evaluate a temozolomide (TMZ)-loaded polyamide-amine dendrimer (PAMAM)‑based nanodrug delivery system, and to explore its ability to target human melanoma (A375) cells in vitro." | 3.85 | Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells. ( Guo, W; Hou, X; Jiang, G; Li, R; Liu, Y; Ma, Y; Tang, J; Xin, Y; Yang, C, 2017) |
| "Included patients (aged ≥18 years) had ≥1 prescription for ipilimumab, vemurafenib, temozolomide or dacarbazine between 1 January 2011 and 31 August 2013; diagnosis of melanoma and metastasis before first use (index date); no index drug use prior to the index date; continuous health plan enrollment for ≥6 months before and ≥3 months after index date." | 3.85 | Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. ( Barber, BL; Batty, N; Chen, YJ; Hines, DM; Ma, Q; Munakata, J; Zhao, Z, 2017) |
| "This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m(2) on days 1-7 and 15-21) in 36 patients with metastatic uveal melanoma (MUM)." | 3.83 | Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma. ( Asselain, B; Bidard, FC; Cassoux, N; Decaudin, D; Diallo, A; Etienne-Grimaldi, MC; Mariani, P; Piperno-Neumann, S; Plancher, C; Rodrigues, M; Servois, V, 2016) |
| " In the case of glioma, temozolomide (TMZ) is the main option for treatment, but it has limited success due to drug resistance." | 3.83 | NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. ( Fortunato, RS; Kajitani, GS; Menck, CF; Quinet, A; Rocha, CR, 2016) |
| "Isolated limb infusion (ILI) with melphalan (LPAM) or temozolomide (TMZ) was performed on rats bearing melanoma xenografts after systemic administration of the N-cadherin antagonist, ADH-1, or saline." | 3.81 | Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. ( Augustine, CK; Beasley, GM; Davies, MA; Deng, W; Dewhirst, MW; Fontanella, A; Lidsky, ME; Padussis, JC; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS, 2015) |
| "The aim of this study was to investigate the effect of Ki67-ZD55-IL-24 with temozolomide (TMZ) against melanoma in mice." | 3.81 | Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo. ( Jiang, G; Li, RH; Liu, YQ; Sun, C; Wei, ZP; Zheng, JN, 2015) |
| "To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed." | 3.81 | MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. ( Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P, 2015) |
| "The alkylating agent temozolomide (TMZ) represents an important component of current melanoma therapy, but overexpression of O6-methyl-guanine DNA methyltransferase (MGMT) in tumor cells confers resistance to TMZ and impairs therapeutic outcome." | 3.81 | A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. ( Chen, TC; Cho, HY; Hofman, FM; Jhaveri, N; Nguyen, J; Rosenstein-Sisson, R; Schönthal, AH; Wang, W, 2015) |
| "Melanoma and other solid cancers are frequently resistant to chemotherapies based on DNA alkylating agents such as dacarbazine and temozolomide." | 3.81 | MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. ( Acosta, JC; Arozarena, I; Barriuso, J; Erice, O; Goicoechea, I; Jones, C; Margison, GP; Smith, MP; Wellbrock, C; White, R, 2015) |
| "In the present study we collected fresh-frozen pretreatment lymph-node metastasis samples (n=14) from melanoma patients with differential response to dacarbazine (DTIC) or temozolomide (TMZ) chemotherapy, to identify proteins with an impact on treatment response." | 3.80 | Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance. ( Azimi, A; Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Lehtiö, J; Pernemalm, M, 2014) |
| "Using cell proliferation and DNA methylation assays, FACS analysis and quantitative-RT-PCR we have characterised the response of a panel of NRAS and BRAF mutant melanoma cell lines to various chemotherapy drugs, amongst them dacarbazine (DTIC) and temozolomide (TMZ) and DNA synthesis inhibitors." | 3.80 | Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. ( Arozarena, I; Erice, O; Ferguson, J; Goicoechea, I; Margison, GP; Wellbrock, C, 2014) |
| "Melanoma exhibits variable resistance to the alkylating agent temozolomide (TMZ)." | 3.80 | Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide. ( Egger, ME; Gomez-Gutierrez, JG; McMasters, KM; McNally, LR; Nitz, J, 2014) |
| " These compounds are derived from the N-acyltyrosine amino acid - a good enzyme substrate for the tyrosinase enzyme, which is significantly overexpressed in melanoma cells." | 3.79 | Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines. ( Almeida, J; Cabral, G; Francisco, AP; Mendes, E; Monteiro, AS; Nunes, R; Pereira, JD; Perry, MJ; Severino, P; Sousa, A; Videira, PA, 2013) |
| " On the basis of this, we conducted a study on DC-based vaccination in advanced melanoma, adding low-dose temozolomide to obtain lymphodepletion." | 3.79 | Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. ( Ancarani, V; Ascierto, PA; Baravelli, S; de Rosa, F; Fiammenghi, L; Gentilcore, G; Granato, AM; Guidoboni, M; Nicoletti, SV; Pancisi, E; Petrini, M; Riccobon, A; Ridolfi, L; Ridolfi, R; Scarpi, E; Simeone, E; Valmorri, L, 2013) |
| "Compared with temozolomide chemotherapy, the MEK inhibitor selumetinib extended progression-free survival by nearly 9 weeks in patients with melanoma of the eye participating in a phase II trial, making it the first effective drug for the rare disease." | 3.79 | Selumetinib shows promise in metastatic uveal melanoma. ( , 2013) |
| "The major cytotoxic DNA adduct induced by temozolomide and other methylating agents used in malignant glioma and metastasized melanoma therapy is O(6)-methylguanine (O(6)-MeG)." | 3.79 | Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. ( Eich, M; Kaina, B; Nikolova, T; Roos, WP, 2013) |
| "Mebendazole (MBZ) was identified as a promising therapeutic on the basis of its ability to induce apoptosis in melanoma cell lines through a B-cell lymphoma 2 (BCL2)-dependent mechanism." | 3.79 | XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. ( Byron, SA; Doudican, NA; Orlow, SJ; Pollock, PM, 2013) |
| "The DNA alkylating agent temozolomide (TMZ) is widely used in the treatment of human malignancies such as glioma and melanoma." | 3.78 | Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. ( Amin, S; Cheng, Y; Huber-Keener, KJ; Liao, J; Ren, X; Sharma, AK; Sk, UH; Sun, YW; Yang, JM; Zhang, L; Zhang, Y, 2012) |
| "First line treatment of metastatic melanoma includes the methylating agent dacarbazine or its analogue temozolomide (TMZ) with improved pharmacokinetics and tolerability." | 3.77 | The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. ( Caccuri, AM; Cuzzocrea, S; Dorio, AS; Federici, G; Graziani, G; Mazzon, E; Muzi, A; Sau, A; Tentori, L; Vernole, P, 2011) |
| "Autophagy was measured in tumor biopsies obtained from metastatic melanoma patients enrolled on a phase II trial of temozolomide and sorafenib and correlated to clinical outcome." | 3.77 | Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. ( Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D, 2011) |
| "The efficacy of temozolomide in melanoma treatment is low (response rate <20%) and may depend on the activity of O-methylguanine DNA methyltransferase (MGMT) and mismatch repair." | 3.77 | Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. ( Boeckmann, L; Emmert, S; Kuschal, C; Nickel, AC; Schaefer, A; Schön, MP; Thomale, J; Thoms, KM, 2011) |
| " Recently, the alkylating agent temozolomide, which has demonstrated activity in patients with brain metastasis and primary tumors, was used alongside WBR to delay brain metastasis recurrence, increase survival, and improve quality-of-life in patients with brain metastases." | 3.77 | Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. ( Chen, R; Devito, N; Pan, E; Yu, M, 2011) |
| "This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma." | 3.76 | Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy? ( Bearden, JD; Behl, D; Brown, PD; Deming, RL; Markovic, SN; Rowland, KM; Sande, JR; Schild, SE, 2010) |
| " Pharmacologic characterization (chemosensitivity) was also done in four models using two drugs, temozolomide and fotemustine, currently used in the clinical management of uveal melanoma." | 3.76 | Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. ( Asselain, B; Barillot, E; Bessard, MA; Couturier, J; Dahmani, A; Decaudin, D; Desjardins, L; Donnadieu, MH; Gentien, D; Lantz, O; Laurent, C; Mariani, P; Némati, F; Péguillet, I; Piperno-Neumann, S; Plancher, C; Reyes, C; Robert, D; Roman-Roman, S; Sastre-Garau, X; Saule, S, 2010) |
| "All patients with metastatic melanoma treated with either dacarbazine (DTIC) or temozolomide (TMZ) at the British Columbia Cancer Agency (BCCA) from January 1, 1988 to February 1, 2006 were identified through the BCCA pharmacy electronic database, which was then linked to the surveillance and outcomes unit to identify patients with LTS, defined as survival > or =18 months following chemotherapy." | 3.76 | Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide. ( Kim, C; Klasa, R; Kovacic, L; Lee, CW; Savage, KJ; Shah, A, 2010) |
| "The alkylating agent dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved." | 3.76 | Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. ( Burd, R; Limesand, KH; Mendoza, EE; Mitchell, GC; Radhakrishnan, VM; Sittadjody, S; Thangasamy, T, 2010) |
| "Despite limited clinical efficacy, treatment with dacarbazine or temozolomide (TMZ) remains the standard therapy for metastatic melanoma." | 3.76 | MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. ( Dummer, R; Edler, L; Hassel, JC; Kurzen, H; Mauch, C; Moll, I; Rass, K; Schadendorf, D; Spieth, K; Stresemann, C; Sucker, A, 2010) |
| "Despite objective response rates of only approximately 13%, temozolomide remains one of the most effective single chemotherapy agents against metastatic melanoma, second only to dacarbazine, the current standard of care for systemic treatment of melanoma." | 3.75 | Genomic and molecular profiling predicts response to temozolomide in melanoma. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Nevins, JR; Potti, A; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2009) |
| " A 67-year-old renal transplant recipient developed a nodular malignant melanoma after 30 years of immunosuppression with azathioprine and prednisolone." | 3.75 | Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. ( Guenova, E; Hoetzenecker, W; Lichte, V; Moehrle, M; Roecken, M; Schaller, M; Woelbing, F, 2009) |
| "The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair." | 3.75 | Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians. ( Boeckmann, L; Brockmoeller, J; Emmert, S; Gutzmer, R; Has, C; Kunz, M; Kuschal, C; Laspe, P; Rosenberger, A; Schirmer, M; Schoen, MP; Struever, D; Thoms, KM, 2009) |
| "Efforts to improve melanoma response rates to temozolomide (TMZ) have thus far been unsuccessful." | 3.75 | Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. ( Chen, M; Doudican, N; Orlow, SJ; Osman, I; Rose, AE, 2009) |
| " This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers." | 3.74 | PARP inhibitors and cancer therapy - early results and potential applications. ( Jones, C; Plummer, ER, 2008) |
| "Dasatinib has both anti-proliferative and anti-invasive effects in melanoma cells and combined with chemotherapy may have clinical benefit in the treatment of malignant melanoma." | 3.74 | Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. ( Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N, 2008) |
| "Five different human melanoma xenografts were used in a xenograft model of extremity melanoma to evaluate the variability of tumor response to regionally administered melphalan or temozolomide and to determine if various components of pertinent drug resistance pathways for melphalan [glutathione S-transferase (GST)/glutathione] and temozolomide [O(6)-alkylguanine DNA alkyltranferase (AGT)/mismatch repair (MMR)] could be predictive of tumor response." | 3.74 | Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. ( Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA, 2007) |
| "Temozolomide (TMZ), a DNA alkylating agent used in the treatment of melanoma, is believed to mediate its effect by addition of a methyl group to the O(6) position of guanine in DNA." | 3.74 | Temozolomide induces senescence but not apoptosis in human melanoma cells. ( Allen, J; Avery-Kiejda, KA; Hersey, P; Mhaidat, NM; Scott, RJ; Zhang, XD, 2007) |
| "Temozolomide is an oral alkylating agent used in the treatment of metastatic melanoma." | 3.74 | Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma. ( Neff, WJ; Nystrom, KK; Pick, AM, 2008) |
| " In this study, cilengitide was tested in combination with the methylating agent temozolomide (TMZ), a well-tolerated anticancer drug with favourable pharmacokinetic properties currently used for the therapy of metastatic melanoma." | 3.74 | The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. ( Dorio, AS; Graziani, G; Lacal, PM; Muzi, A; Navarra, P; Ruffini, F; Tentori, L, 2008) |
| "Clinical trials have shown temozolomide to be an effective agent for treatment of malignant melanoma." | 3.73 | Skin delivery potency and antitumor activities of temozolomide ester prodrugs. ( Conway, BR; Suppasansatorn, P; Wang, G; Wang, W; Wang, Y, 2006) |
| "The aim of this study was to determine the efficacy and tolerability of a biochemotherapy regimen, including low-dose subcutaneous interleukin-2 and temozolomide, in patients with metastatic melanoma." | 3.73 | Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Carrera, C; Castel, T; Conill, C; Gascón, P; González Cao, M; Herrero, J; Malvehy, J; Martí, R; Martín, M; Mellado, B; Puig, S; Sánchez, M, 2006) |
| "This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT)." | 3.73 | Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. ( Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y, 2006) |
| " Aim of the present study was to investigate the molecular mechanisms underlying acquired resistance of melanoma cells to TMZ and the effect of O6-benzylguanine (BG), a specific MGMT inhibitor, on the development of a TMZ-resistant phenotype." | 3.73 | A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. ( Alvino, E; Bonmassar, E; Caporali, S; Caporaso, P; Castiglia, D; D'Atri, S; Fischer, F; Jiricny, J; Lacal, PM; Marra, G; Pepponi, R; Zambruno, G, 2006) |
| "In the present study, we have investigated the influence of telomerase inhibition in chemosensitivity of melanoma cells to temozolomide (TMZ), a methylating agent with promising antitumor activity against metastatic melanoma." | 3.72 | Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor. ( Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M, 2003) |
| "Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine." | 3.72 | Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004) |
| "Ten patients with malignant melanoma and phototoxic reactions under dacarbazine or 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) chemotherapy were investigated." | 3.72 | Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. ( Geilen, CC; Georgieva, J; Orfanos, CE; Treudler, R, 2004) |
| "The present observation suggests that temozolomide may be an active and well tolerated treatment for malignant melanoma brain metastases." | 3.72 | Complete response of multiple melanoma brain metastases after treatment with temozolomide. ( Dvorak, J; Hadzi-Nikolov, D; Melichar, B; Petera, J; Zizka, J, 2004) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 3.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| " 11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | 3.71 | [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| " In melanoma specimens taken from a patient 3 h post-treatment with temozolomide, MGMT levels were reduced by 70%." | 3.69 | Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. ( Alas, LG; Belanich, M; Citron, ML; Dolan, ME; Gander, M; Kibitel, JT; Lejeune, FJ; Li, BF; Pastor, MA; Randall, T; Schold, SC; Wasserman, P; White, AB; Yarosh, DB, 1996) |
| "Melanoma has been recognized as one of the most immunogenic malignancies; therefore, understanding the mechanisms of tumor-immune interaction is key for developing more efficient treatments." | 2.84 | Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients. ( Dronca, RS; Ivanov, LV; Kottschade, LA; Leontovich, AA; Markovic, SN; Nevala, WK; Thompson, MA, 2017) |
| "Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation." | 2.79 | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. ( Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD, 2014) |
| "2 mg/kg three times weekly for 2 weeks (starting on day 1), in combination with oral panobinostat 10, 20, or 30 mg every 96 h (starting on day 8), and oral temozolomide 150 mg/m(2)/day on days 9 through 13." | 2.79 | Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). ( Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C, 2014) |
| "The LMD source was breast cancer (53 %) and non-small-cell lung cancer (37 %)." | 2.77 | Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. ( Balañá, C; Bruna, J; Chacón, I; Gil, M; Langa, JM; Martín, M; Segura, PP, 2012) |
| "Temozolomide was administered at a dose of 75 mg/m/day from days 2-6 and subsequent cohorts were dose escalated by 25 mg/m increments." | 2.76 | Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors. ( Lee, FC; Mangalik, A; Movva, S; Parks, V; Rabinowitz, I; Verschraegen, CF, 2011) |
| "Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies." | 2.74 | A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. ( Abdi, E; Beith, J; Corrie, PG; Kefford, RF; Kotasek, D; Margison, GP; Middleton, MR; Mortimer, P; Palmer, C; Ranson, M; Thomas, NP; Watson, AJ, 2009) |
| "33 patients with brain metastases were included in the study and treated with TMZ 60 mg/m2/day (days 1-16) concomitantly with WBI (36 Gy/12 fractions given in 16 days)." | 2.73 | Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. ( Balafouta, MJ; Kolokouris, D; Kouloulias, VE; Kouvaris, JR; Miliadou, A; Papacharalampous, XN; Vlahos, LJ, 2007) |
| " Accordingly, a clinical trial using oral temozolomide (TMZ) and subcutaneous PEG-interferon alpha-2b (PEG) in patients with metastatic melanoma was designed to determine the maximal tolerated dosage of both drugs and the antitumoral response." | 2.73 | Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. ( Bedane, C; Cupissol, D; Delaunay, M; Dereure, O; Dreno, B; Guillot, B; Khamari, A; Picot, MC, 2008) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 2.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Temozolomide is a rapidly absorbed chemotherapeutic agent, achieving significant central nervous system penetration." | 2.72 | Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. ( Hansson, J; Månsson-Brahme, E; Masucci, GV; Nilsson, B; Ragnarsson-Olding, B; Wagenius, G, 2006) |
| " Therefore, the authors initiated a Phase I study to determine the pharmacokinetics and safety profile of temozolomide (TMZ), a novel oral alkylating agent known to cross the blood-brain barrier, in combination with interferon alpha-2b (IFN-alpha2b)." | 2.71 | Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. ( Agarwala, SS; Kirkwood, JM, 2003) |
| "Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS." | 2.71 | Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. ( Agarwala, SS; Atkins, M; Buzaid, A; Czarnetski, B; Dreno, B; Gore, M; Kirkwood, JM; Rankin, EM; Skarlos, D; Thatcher, N, 2004) |
| "Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%." | 2.71 | The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. ( Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D, 2004) |
| "To evaluate the efficacy of temozolomide (TMZ) combined with cisplatin (CDDP) in terms of response rate, time to progression (TTP) and overall survival (OS), as well as the tolerability of the regimen in patients with brain metastases from solid tumors." | 2.71 | Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005) |
| "Temozolomide (TMZ) is an oral alkylating agent that produces methyl adducts at the 0." | 2.71 | Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. ( Bafaloukos, D; Briassoulis, E; Chalkidou, S; Christodoulou, C; Efstathiou, E; Fountzilas, G; Gogas, H; Iconomou, T; Kalofonos, H; Kouroussis, C; Linardou, E; Panagiotou, P; Polyzos, A; Tsoutsos, D, 2005) |
| "Temozolomide is an oral alkylating agent that has equivalent activity to dacarbazine, but it has the advantage of CNS penetration." | 2.71 | A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. ( Anderson, C; Baron, A; Gibbs, P; Gonzalez, R; Lewis, KD; O'Day, S; Richards, J; Russ, P; Weber, J; Zeng, C, 2005) |
| " The absolute bioavailability of TMZ was 0." | 2.69 | Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. ( Bauer, J; Biollaz, J; Buclin, T; Decosterd, LA; Gander, M; Lejeune, F; Leyvraz, S; Marzolini, C; Shen, F, 1998) |
| "Fotemustine 100 mg/m2 was given intravenously on day 2, 4 hours after TMZ." | 2.69 | Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. ( Belanich, M; Biollaz, J; Bonfanti, M; Colella, G; D'Incalci, M; Decosterd, L; Gander, M; Lejeune, F; Leyvraz, S; Liénard, D; Marzolini, C; Perey, L; Shen, F; Yarosh, D, 1999) |
| " Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1." | 2.69 | Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. ( Batra, V; Beale, P; Brada, M; Cutler, D; Dugan, M; Judson, I; Moore, S; Reidenberg, P; Statkevich, P, 1999) |
| "Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 and subsequently was given orally up to 1,200 mg m-2." | 2.67 | Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). ( Blackledge, GR; Brampton, MH; Hoffman, R; Newlands, ES; Quarterman, CP; Rustin, GJ; Slack, JA; Smith, DB; Stevens, MF; Stuart, NS, 1992) |
| " We retrieved evidence on treatment-related grade III/IV adverse events, progression-free survival (PFS) and overall survival (OS)." | 2.61 | A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. ( Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM, 2019) |
| "nab-Paclitaxel has single agent activity in chemotherapy-naïve untreated metastatic melanoma which compares favorably to the activity of weekly paclitaxel or single agent dacarbazine." | 2.61 | Efficacy of nab-paclitaxel in treating metastatic melanoma. ( Specenier, P, 2019) |
| "Treatments for advanced melanoma are associated with different adverse events (AEs), which may be costly to manage." | 2.58 | Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. ( Chmielowski, B; Copley-Merriman, C; Liu, FX; Mauskopf, J; Stevinson, K; Wang, J; Zimovetz, EA, 2018) |
| "Cutaneous melanoma is the most deadly cutaneous neoplasm." | 2.53 | The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. ( Arnold, A; Braun, R; Dummer, R; Guckenberger, M; Hunger, RE; Lindenblatt, N; Michielin, O; Mihic-Probst, D; Najafi, Y; Siano, M; von Moos, R, 2016) |
| " Overall, we have verified that TMZ in addition to being an alkylating and cytotoxic chemotherapy, also possess immune modulatory effect in MM patients treated with standard dosage of TMZ." | 2.49 | Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer. ( Iversen, TZ, 2013) |
| "Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain tumours like glioblastoma multiforme and oligodendroglioma." | 2.49 | Temozolomide and unusual indications: review of literature. ( Abrial, C; Durando, X; Gadea, E; Gimbergues, P; Planchat, E; Tatar, Z; Thivat, E, 2013) |
| "Brain metastases affect 37% of patients suffering from metastatic melanoma, and their prognosis remains poor, with an overall survival lower than six months." | 2.49 | [Therapeutic strategies and systemic treatment of brain melanoma metastases]. ( Brocard, L; Daste, A; Durando, X; Gimbergues, P; Magné, N; Mansard, S; Thivat, E, 2013) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for the treatment of glioma, astrocytoma, and melanoma." | 2.47 | A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. ( Jiang, G; Liu, YQ; Pei, DS; Wei, ZP; Xin, Y; Zheng, JN, 2011) |
| "Melanoma is a tumour derived from melanocytes, cells of neuroectodermal origin." | 2.47 | [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities]. ( Czyż, M; Koprowska, K, 2011) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | 2.42 | [Therapy of malignant melanoma at the stage of distant metastasis]. ( Eigentler, TK; Garbe, C, 2004) |
| "Melanoma is the third most common metastatic brain tumor in the United States and is a major cause of morbidity and mortality." | 2.42 | Management of brain metastases in patients with melanoma. ( Agarwala, SS; Tarhini, AA, 2004) |
| "Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC)." | 2.41 | Temozolomide: a novel oral alkylating agent. ( Danson, SJ; Middleton, MR, 2001) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 2.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| "Although melanoma is a relatively chemoresistant malignancy, systemic chemotherapy remains the primary treatment for metastatic melanoma." | 2.41 | New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. ( Hwu, WJ, 2000) |
| "Temozolomide (TMZ) is a chemotherapy agent used to treat primary central nervous system tumors." | 1.91 | Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis. ( Azambuja, JH; Braganhol, E; de Cássia Sant'ana, R; de Souza, PO; Debom, GN; Fachel, FNS; Gelsleichter, NE; Lenz, GS; Michels, LR; Roliano, GG; Teixeira, FC; Teixeira, HF; Visioli, F, 2023) |
| "Temozolomide was administered orally once per day at a dosage of 200 mg/m2/d for five consecutive days about every 4 weeks." | 1.56 | Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. ( Cao, F; Chen, S; Fan, W; Li, D; Ma, W; Qi, H; Shen, L; Song, Z; Wen, X; Wu, Y; Xie, L; Zhang, X, 2020) |
| "A novel core‑shell type thermo‑nanoparticle (CSTNP) co‑loaded with temozolomide (TMZ) and the fluorescein new indocyanine green dye IR820 (termed IT‑CSTNPs) was designed and combined with a near‑infrared (NIR) laser to realize its photothermal conversion." | 1.51 | Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells. ( Hou, X; Jiang, G; Li, X; Liu, W; Liu, Y; Pang, Y; Yang, C, 2019) |
| "Malignant melanoma is the deadliest form of skin cancer and highly chemoresistant." | 1.51 | Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways. ( Baek, SB; Jung, HJ; Lim, HN, 2019) |
| "Glioblastoma is the most common primary brain tumor in adults." | 1.51 | ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. ( Al-Omaishi, S; Celebre, A; Chan, J; Das, S; Dirks, PB; Ghannad-Zadeh, K; Guan, J; Isaev, K; Kaskun, O; Moran, MF; Morrissy, AS; Munoz, DG; Reimand, J; Sachdeva, R; Smiljanic, S; Taylor, MD; Tong, J; Wilson, TM; Wu, M, 2019) |
| "The incidence of malignant melanoma is increasing." | 1.48 | Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment. ( Abramov, I; Khochenkov, D; Prokofieva, A; Ryabaya, O; Stepanova, E; Zasedatelev, A, 2018) |
| "Melanoma is a recalcitrant cancer." | 1.48 | Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. ( Chmielowski, B; Dry, SM; Eckardt, MA; Eilber, FC; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Li, Y; Miyake, K; Miyake, M; Nelson, SD; Ohshiro, H; Razmjooei, S; Russell, TA; Singh, AS; Singh, SR; Sugisawa, N; Tan, Y; Unno, M; Wangsiricharoen, S; Zhang, Z; Zhao, M, 2018) |
| "One of the most common treatments for melanoma is surgery, followed by various combinations of chemotherapy drugs." | 1.46 | Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism. ( Chang, X; Lian, S; Zhang, H; Zhu, W, 2017) |
| "Melanoma is the most lethal type of skin cancer." | 1.46 | MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. ( Chammas, R; Cirilo, PDR; Corrêa, BRS; de Sousa Andrade, LN; Furuya, TK; Penalva, LOF; Qiao, M, 2017) |
| "Malignant melanoma is an aggressive, highly lethal dermatological malignancy." | 1.43 | DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines. ( Chen, YP; Feng, SX; Hou, XY; Jiang, G; Jiang, XX; Liu, YQ; Xu, XF; Yang, CS; Yang, M, 2016) |
| "Of clinical relevance, pretreatment of melanoma cells with a mitogen-activated protein kinase pathway inhibitor, which induced G1 arrest, resulted in resistance to temozolomide or bortezomib." | 1.43 | Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. ( Beaumont, KA; Daignault, SM; Gabrielli, B; Haass, NK; Hill, DS; Lui, GYL; Sharp, DM; Weninger, W, 2016) |
| " The present study used a patient-derived orthotopic xenograft (PDOX) nude-mouse model of melanoma with a BRAF-V600E mutation to determine the efficacy of temozolomide (TEM) combined with tumor-targeting Salmonella typhimurium A1-R." | 1.43 | Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. ( Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, A; Unno, M; Zhang, Y; Zhao, M, 2016) |
| "We report myelitis with consequent paraplegia as a potential neurological immune-related side effect of ipilimumab." | 1.40 | Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. ( Ahmad, MW; Alken, S; Colleran, GC; Fitzpatrick, D; Kavanagh, EC; Kelly, CM; Lyons, TG; Murray, B; O'Kane, GM, 2014) |
| "Malignant melanoma is one of the most lethal and aggressive human malignancies." | 1.39 | A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. ( Cheng, Q; Jiang, AJ; Jiang, G; Li, LT; Tian, H; Zheng, JN, 2013) |
| "The presence of subcutaneous metastases raised the suspicion for metastatic melanoma; however, pathological confirmation remained the ultimate tool to reach the final diagnosis." | 1.39 | Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. ( Ejaz, S; Habra, MA; Henderson, SA; Shawa, H, 2013) |
| "Metastatic melanoma has poor prognosis and is refractory to most conventional chemotherapies." | 1.37 | The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. ( Cooper, DA; Fujita, M; Goldstein, NB; Norris, DA; Partyka, KA; Reuland, SN; Shellman, YG, 2011) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 1.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| " Drug combination of TMZ plus BG and PHA-848125 produced additive or synergistic effects on cell growth, depending on the cell line." | 1.36 | The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. ( Alvino, E; Bonmassar, E; Brasca, MG; Caporali, S; Castiglia, D; Ciomei, M; Covaciu, C; D'Atri, S; Garbin, A; Levati, L; Starace, G, 2010) |
| "Uveal melanoma is refractory to chemotherapy." | 1.35 | Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo. ( Aldrich, W; Dombos, C; Triozzi, PL, 2008) |
| "Melanoma is the most malignant of skin cancers, highly resistant to chemotherapy and radiotherapy." | 1.35 | Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. ( Bocangel, D; Chada, S; Ekmekcioglu, S; Grimm, EA; Poindexter, N; Ramesh, R; Zheng, M, 2008) |
| "Malignant melanomas are highly resistant to chemotherapy." | 1.35 | Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009) |
| "Primary vaginal melanoma is a rare, highly malignant, and poor prognostic disease." | 1.35 | Primary malignant melanoma of the vagina. ( Baloglu, A; Bezircioglu, I; Cetinkaya, B; Yavuzcan, A, 2009) |
| "First clinical reports on treating brain metastases with temozolomide describe varying effects." | 1.35 | Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. ( Heppner, FL; Ingold, B; Moch, H; Schraml, P, 2009) |
| "Temozolomide (TMZ) is a methylating agent that spontaneously decomposes into the active metabolite of dacarbazine, the most effective agent for the systemic treatment of melanoma." | 1.34 | Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity. ( Bonmassar, E; Caporali, S; Caporaso, P; D'Atri, S; Falcinelli, S; Pagani, E; Pepponi, R; Turriziani, M, 2007) |
| "Indeed melanomas have proven resistant to apoptosis (type I programmed cell death (PCD)) and consequently to most chemotherapy and immunotherapy." | 1.34 | Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. ( De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S, 2007) |
| "Brain metastases are an alarming complication of advanced melanoma, frequently contributing to patient demise." | 1.34 | Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. ( Boucher, KM; Jensen, RL; Leachman, SA; Majer, M; Samlowski, WE; Shrieve, DC; Wang, M; Watson, GA, 2007) |
| "Sixty four patients with melanoma brain metastases were treated in our department within a 15-year period." | 1.33 | Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. ( Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA, 2005) |
| "The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested." | 1.33 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. ( Forini, O; Gold, B; Graziani, G; Lacal, PM; Leonetti, C; Li, W; Muzi, A; Ruffini, F; Scarsella, M; Tentori, L; Vergati, M; Zhang, J, 2005) |
| "Temozolomide (TMZ) has shown efficacy in the treatment of metastatic melanoma." | 1.33 | Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases. ( Castel, T; Conill, C; Domingo-Doménech, J; Gallego, R; Jorcano, S; Malvehy, J; Puig, S; Sánchez, M; Vilella, R, 2006) |
| " This study also analyzed the ratio of the toxic effect of TMZ on MNC and on tumor cells (i." | 1.32 | DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system. ( Alvino, E; Bonmassar, L; D'Atri, S; Falcinelli, S; Fuggetta, MP; Guadagni, F; Lacal, PM; Pagani, E; Passarelli, F; Pepponi, R; Prete, SP; Turriziani, M, 2003) |
| "Temozolomide (TMZ) displays efficacy for the treatment of metastatic melanoma." | 1.32 | [Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation]. ( Castel, T; Conill, C; Fernández-Ibiza, J; Malvehy, J; Puig, S; Sánchez, M, 2004) |
| "Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease." | 1.32 | In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (3.15) | 18.2507 |
| 2000's | 139 (43.85) | 29.6817 |
| 2010's | 152 (47.95) | 24.3611 |
| 2020's | 16 (5.05) | 2.80 |
| Authors | Studies |
|---|---|
| Monteiro, AS | 1 |
| Almeida, J | 1 |
| Cabral, G | 1 |
| Severino, P | 1 |
| Videira, PA | 1 |
| Sousa, A | 2 |
| Nunes, R | 1 |
| Pereira, JD | 2 |
| Francisco, AP | 2 |
| Perry, MJ | 2 |
| Mendes, E | 2 |
| Santos, F | 1 |
| Gaspar, MM | 1 |
| Calado, S | 1 |
| Ambur, A | 1 |
| Ambur, L | 1 |
| Khan, L | 1 |
| Nathoo, R | 1 |
| Zhou, L | 4 |
| Yang, Y | 3 |
| Si, L | 3 |
| Chi, Z | 3 |
| Sheng, X | 3 |
| Lian, B | 3 |
| Wang, X | 7 |
| Tang, B | 3 |
| Mao, L | 3 |
| Yan, X | 2 |
| Li, S | 5 |
| Bai, X | 2 |
| Guo, J | 4 |
| Cui, C | 3 |
| Liu, C | 4 |
| Liu, J | 1 |
| Shao, J | 1 |
| Huang, C | 2 |
| Dai, X | 1 |
| Shen, Y | 2 |
| Hou, W | 1 |
| Yu, Y | 2 |
| Friedlander, P | 2 |
| Morgan, LR | 1 |
| Benes, EN | 1 |
| Rodgers, AH | 1 |
| Jursic, B | 1 |
| Gelsleichter, NE | 1 |
| de Souza, PO | 1 |
| Teixeira, FC | 1 |
| Debom, GN | 1 |
| Lenz, GS | 1 |
| Roliano, GG | 1 |
| de Cássia Sant'ana, R | 1 |
| Visioli, F | 1 |
| Fachel, FNS | 1 |
| Michels, LR | 1 |
| Azambuja, JH | 1 |
| Teixeira, HF | 1 |
| Braganhol, E | 1 |
| Lian, W | 1 |
| Zheng, X | 1 |
| Li, C | 2 |
| Kong, Y | 2 |
| Dai, J | 1 |
| Wei, X | 1 |
| Li, J | 8 |
| Duan, R | 1 |
| Xu, H | 1 |
| Wu, X | 2 |
| Cheng, F | 1 |
| Zhang, C | 1 |
| Xia, F | 1 |
| Pang, Z | 1 |
| Goodman, RS | 1 |
| Jung, S | 1 |
| Quintos, J | 1 |
| Johnson, DB | 1 |
| Hou, X | 3 |
| Pang, Y | 2 |
| Li, X | 11 |
| Yang, C | 3 |
| Liu, W | 2 |
| Jiang, G | 11 |
| Liu, Y | 8 |
| Mattila, KE | 1 |
| Vihinen, P | 1 |
| Ramadan, S | 1 |
| Skyttä, T | 1 |
| Tiainen, L | 1 |
| Vuoristo, MS | 1 |
| Tyynelä-Korhonen, K | 1 |
| Koivunen, J | 1 |
| Kohtamäki, L | 1 |
| Mäkelä, S | 1 |
| Hernberg, M | 1 |
| Andrade, LNS | 1 |
| Otake, AH | 1 |
| Cardim, SGB | 1 |
| da Silva, FI | 1 |
| Ikoma Sakamoto, MM | 1 |
| Furuya, TK | 2 |
| Uno, M | 1 |
| Pasini, FS | 1 |
| Chammas, R | 2 |
| Franken, MG | 1 |
| Leeneman, B | 1 |
| Gheorghe, M | 1 |
| Uyl-de Groot, CA | 1 |
| Haanen, JBAG | 1 |
| van Baal, PHM | 1 |
| Sahu, P | 1 |
| Kashaw, SK | 1 |
| Sau, S | 1 |
| Kushwah, V | 1 |
| Jain, S | 1 |
| Iyer, AK | 1 |
| Karachaliou, GS | 1 |
| Ayvali, F | 1 |
| Collichio, FA | 1 |
| Lee, CB | 1 |
| Ivanova, A | 1 |
| Ollila, DW | 1 |
| Moschos, SJ | 2 |
| Tas, F | 3 |
| Erturk, K | 1 |
| Chen, S | 3 |
| Zhang, X | 5 |
| Shen, L | 1 |
| Qi, H | 1 |
| Ma, W | 1 |
| Cao, F | 1 |
| Xie, L | 1 |
| Song, Z | 1 |
| Wu, Y | 3 |
| Li, D | 3 |
| Wen, X | 1 |
| Fan, W | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 4 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 3 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 3 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, Y | 4 |
| Chen, L | 3 |
| Shan, A | 1 |
| Zhao, H | 2 |
| Wu, M | 3 |
| Ma, Q | 2 |
| Wang, J | 6 |
| Zhang, E | 1 |
| Zhang, J | 4 |
| Li, Y | 9 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Wang, Y | 4 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 2 |
| Liu, X | 1 |
| Ren, Y | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, W | 3 |
| Wang, S | 2 |
| Hou, J | 1 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 2 |
| Zhu, J | 2 |
| Zhang, L | 3 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 2 |
| Qu, Y | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 2 |
| Hu, W | 1 |
| Zhang, Y | 6 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 3 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 2 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 2 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Zhang, M | 4 |
| Zhang, H | 2 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 2 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 3 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 3 |
| Zhang, T | 2 |
| Wang, Q | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Chen, H | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 2 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 2 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 3 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 2 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 2 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 2 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 2 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 1 |
| He, Z | 1 |
| Chen, B | 1 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 1 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 2 |
| Ma, H | 1 |
| Ren, X | 2 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Dirilenoglu, F | 1 |
| Yukselen, OO | 1 |
| Mocan, G | 1 |
| Wang, B | 1 |
| Qu, C | 1 |
| Wei, J | 1 |
| Meng, L | 1 |
| Xin, Y | 3 |
| Dong, L | 1 |
| Niessner, H | 2 |
| Kosnopfel, C | 1 |
| Sinnberg, T | 2 |
| Beck, D | 1 |
| Krieg, K | 1 |
| Wanke, I | 1 |
| Lasithiotakis, K | 2 |
| Bonin, M | 1 |
| Garbe, C | 7 |
| Meier, F | 2 |
| Zhu, W | 1 |
| Lian, S | 1 |
| Patel, SP | 3 |
| Kim, DW | 1 |
| Bassett, RL | 2 |
| Cain, S | 4 |
| Washington, E | 1 |
| Hwu, WJ | 14 |
| Kim, KB | 7 |
| Papadopoulos, NE | 5 |
| Homsi, J | 3 |
| Hwu, P | 7 |
| Bedikian, AY | 8 |
| Nath, K | 1 |
| Nelson, DS | 1 |
| Roman, J | 1 |
| Putt, ME | 1 |
| Lee, SC | 1 |
| Leeper, DB | 1 |
| Glickson, JD | 1 |
| Keidar, M | 1 |
| Yan, D | 1 |
| Beilis, II | 1 |
| Trink, B | 1 |
| Sherman, JH | 1 |
| Cirilo, PDR | 1 |
| de Sousa Andrade, LN | 1 |
| Corrêa, BRS | 1 |
| Qiao, M | 1 |
| Penalva, LOF | 1 |
| Clemente, N | 1 |
| Ferrara, B | 1 |
| Gigliotti, CL | 1 |
| Boggio, E | 1 |
| Capucchio, MT | 1 |
| Biasibetti, E | 1 |
| Schiffer, D | 1 |
| Mellai, M | 1 |
| Annovazzi, L | 1 |
| Cangemi, L | 1 |
| Muntoni, E | 1 |
| Miglio, G | 1 |
| Dianzani, U | 1 |
| Battaglia, L | 1 |
| Dianzani, C | 1 |
| Choi, DK | 1 |
| Pillay-Smiley, N | 1 |
| Marzec, S | 1 |
| Wadhwani, NR | 1 |
| DiPatri, AJ | 1 |
| Tomita, T | 1 |
| Lulla, RR | 1 |
| Tang, J | 3 |
| Zhou, H | 1 |
| Chen, C | 1 |
| Ryabaya, O | 1 |
| Prokofieva, A | 1 |
| Khochenkov, D | 1 |
| Abramov, I | 1 |
| Zasedatelev, A | 1 |
| Stepanova, E | 1 |
| Copley-Merriman, C | 1 |
| Stevinson, K | 1 |
| Liu, FX | 1 |
| Mauskopf, J | 1 |
| Zimovetz, EA | 1 |
| Chmielowski, B | 3 |
| Kawaguchi, K | 2 |
| Higuchi, T | 1 |
| Han, Q | 1 |
| Tan, Y | 1 |
| Igarashi, K | 2 |
| Zhao, M | 2 |
| Miyake, K | 1 |
| Kiyuna, T | 2 |
| Miyake, M | 1 |
| Ohshiro, H | 1 |
| Sugisawa, N | 1 |
| Zhang, Z | 1 |
| Razmjooei, S | 1 |
| Wangsiricharoen, S | 1 |
| Nelson, SD | 2 |
| Russell, TA | 2 |
| Dry, SM | 2 |
| Eckardt, MA | 1 |
| Singh, AS | 1 |
| Singh, SR | 1 |
| Eilber, FC | 2 |
| Unno, M | 2 |
| Hoffman, RM | 2 |
| Yang, M | 2 |
| Tao, Y | 1 |
| Huang, Q | 1 |
| Guo, W | 2 |
| Feng, S | 1 |
| Jiang, A | 1 |
| Allavena, G | 1 |
| Del Bello, B | 1 |
| Tini, P | 1 |
| Volpi, N | 1 |
| Valacchi, G | 1 |
| Miracco, C | 1 |
| Pirtoli, L | 1 |
| Maellaro, E | 1 |
| Donia, M | 1 |
| Ellebaek, E | 1 |
| Øllegaard, TH | 1 |
| Duval, L | 1 |
| Aaby, JB | 1 |
| Hoejberg, L | 1 |
| Køhler, UH | 1 |
| Schmidt, H | 1 |
| Bastholt, L | 2 |
| Svane, IM | 2 |
| Specenier, P | 1 |
| Swami, U | 1 |
| Monga, V | 1 |
| Freesmeier, M | 1 |
| Zhang, W | 1 |
| Bossler, AD | 1 |
| Zakharia, Y | 1 |
| Milhem, M | 2 |
| Makita, K | 1 |
| Hara, H | 1 |
| Sano, E | 1 |
| Okamoto, Y | 1 |
| Ochiai, Y | 1 |
| Harada, T | 1 |
| Ueda, T | 1 |
| Nakayama, T | 1 |
| Aizawa, S | 1 |
| Yoshino, A | 1 |
| Lim, HN | 1 |
| Baek, SB | 1 |
| Jung, HJ | 1 |
| Sachdeva, R | 1 |
| Smiljanic, S | 1 |
| Kaskun, O | 1 |
| Ghannad-Zadeh, K | 1 |
| Celebre, A | 1 |
| Isaev, K | 1 |
| Morrissy, AS | 1 |
| Guan, J | 1 |
| Tong, J | 1 |
| Chan, J | 1 |
| Wilson, TM | 1 |
| Al-Omaishi, S | 1 |
| Munoz, DG | 1 |
| Dirks, PB | 1 |
| Moran, MF | 1 |
| Taylor, MD | 1 |
| Reimand, J | 1 |
| Plummer, R | 2 |
| Lorigan, P | 3 |
| Steven, N | 1 |
| Scott, L | 1 |
| Middleton, MR | 17 |
| Wilson, RH | 1 |
| Mulligan, E | 1 |
| Curtin, N | 1 |
| Wang, D | 2 |
| Dewji, R | 1 |
| Abbattista, A | 1 |
| Gallo, J | 1 |
| Calvert, H | 2 |
| Marcus, DM | 1 |
| Lowe, M | 1 |
| Khan, MK | 1 |
| Lawson, DH | 2 |
| Crocker, IR | 1 |
| Shelton, JW | 1 |
| Melton, A | 1 |
| Maynard, N | 1 |
| Delman, KA | 1 |
| Carlson, GW | 1 |
| Rizzo, M | 1 |
| Jiang, AJ | 1 |
| Tian, H | 1 |
| Li, LT | 1 |
| Zheng, JN | 4 |
| Janco, JM | 1 |
| Markovic, SN | 5 |
| Weaver, AL | 1 |
| Cliby, WA | 1 |
| Ridolfi, L | 2 |
| Petrini, M | 1 |
| Granato, AM | 1 |
| Gentilcore, G | 1 |
| Simeone, E | 1 |
| Ascierto, PA | 1 |
| Pancisi, E | 1 |
| Ancarani, V | 1 |
| Fiammenghi, L | 1 |
| Guidoboni, M | 1 |
| de Rosa, F | 1 |
| Valmorri, L | 1 |
| Scarpi, E | 1 |
| Nicoletti, SV | 1 |
| Baravelli, S | 1 |
| Riccobon, A | 1 |
| Ridolfi, R | 3 |
| Ejaz, S | 1 |
| Shawa, H | 1 |
| Henderson, SA | 1 |
| Habra, MA | 1 |
| Teimouri, F | 1 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| Eich, M | 2 |
| Roos, WP | 5 |
| Nikolova, T | 1 |
| Kaina, B | 5 |
| Li, RH | 3 |
| Sun, C | 2 |
| Jia, HY | 1 |
| Lei, TC | 1 |
| Liu, YQ | 6 |
| Iversen, TZ | 2 |
| Lipson, EJ | 1 |
| Bodell, MA | 1 |
| Kraus, ES | 1 |
| Sharfman, WH | 1 |
| Leccia, MT | 1 |
| Planchamp, F | 1 |
| Sassolas, B | 2 |
| Combemale, P | 1 |
| Modiano, P | 1 |
| Bedane, C | 3 |
| Cupissol, D | 3 |
| Derrey, S | 1 |
| Dygai-Cochet, I | 1 |
| Lamant, L | 1 |
| Lubrano, V | 1 |
| Mirabel, X | 1 |
| Mourrégot, A | 1 |
| Rougé Bugat, ME | 1 |
| Siegrist, S | 1 |
| Thariat, J | 1 |
| Tiffet, O | 1 |
| Truc, G | 1 |
| Verdoni, L | 1 |
| Mazeau-Woynar, V | 1 |
| Goncalves, MD | 1 |
| Alavi, A | 1 |
| Torigian, DA | 1 |
| Meckbach, D | 1 |
| Keim, U | 1 |
| Richter, S | 1 |
| Leiter, U | 3 |
| Eigentler, TK | 2 |
| Bauer, J | 2 |
| Pflugfelder, A | 1 |
| Büttner, P | 1 |
| Weide, B | 1 |
| Megahed, AI | 1 |
| Koon, HB | 2 |
| Walker, MS | 1 |
| Reyes, C | 2 |
| Kerr, J | 1 |
| Satram-Hoang, S | 1 |
| Stepanski, EJ | 1 |
| Turley, RS | 1 |
| Tokuhisa, Y | 1 |
| Toshimitsu, H | 3 |
| Lidsky, ME | 1 |
| Padussis, JC | 2 |
| Fontanella, A | 1 |
| Deng, W | 1 |
| Augustine, CK | 9 |
| Beasley, GM | 3 |
| Davies, MA | 3 |
| Dewhirst, MW | 1 |
| Tyler, DS | 12 |
| Azimi, A | 1 |
| Pernemalm, M | 1 |
| Frostvik Stolt, M | 2 |
| Hansson, J | 3 |
| Lehtiö, J | 1 |
| Egyházi Brage, S | 2 |
| Hertzman Johansson, C | 2 |
| Alrwas, A | 1 |
| Deburr, TL | 1 |
| Bassett, R | 1 |
| Woodman, SE | 2 |
| Carvajal, RD | 2 |
| Sosman, JA | 6 |
| Quevedo, JF | 1 |
| Milhem, MM | 1 |
| Joshua, AM | 1 |
| Kudchadkar, RR | 1 |
| Linette, GP | 1 |
| Gajewski, TF | 2 |
| Lutzky, J | 2 |
| Lao, CD | 1 |
| Flynn, PJ | 1 |
| Albertini, MR | 1 |
| Sato, T | 1 |
| Lewis, K | 1 |
| Doyle, A | 1 |
| Ancell, K | 1 |
| Panageas, KS | 7 |
| Bluth, M | 1 |
| Hedvat, C | 1 |
| Erinjeri, J | 1 |
| Ambrosini, G | 1 |
| Marr, B | 1 |
| Abramson, DH | 1 |
| Dickson, MA | 1 |
| Wolchok, JD | 7 |
| Chapman, PB | 8 |
| Schwartz, GK | 1 |
| Arozarena, I | 2 |
| Goicoechea, I | 2 |
| Erice, O | 2 |
| Ferguson, J | 1 |
| Margison, GP | 12 |
| Wellbrock, C | 2 |
| Gatti, L | 1 |
| Sevko, A | 1 |
| De Cesare, M | 1 |
| Arrighetti, N | 1 |
| Manenti, G | 1 |
| Ciusani, E | 1 |
| Verderio, P | 1 |
| Ciniselli, CM | 1 |
| Cominetti, D | 1 |
| Carenini, N | 1 |
| Corna, E | 1 |
| Zaffaroni, N | 1 |
| Rodolfo, M | 1 |
| Rivoltini, L | 1 |
| Umansky, V | 1 |
| Perego, P | 1 |
| Rangwala, R | 1 |
| Leone, R | 1 |
| Chang, YC | 1 |
| Fecher, LA | 1 |
| Schuchter, LM | 2 |
| Kramer, A | 1 |
| Tan, KS | 1 |
| Heitjan, DF | 1 |
| Rodgers, G | 1 |
| Gallagher, M | 1 |
| Piao, S | 2 |
| Troxel, AB | 1 |
| Evans, TL | 1 |
| DeMichele, AM | 1 |
| Nathanson, KL | 2 |
| O'Dwyer, PJ | 1 |
| Kaiser, J | 1 |
| Pontiggia, L | 1 |
| Davis, LE | 1 |
| Amaravadi, RK | 2 |
| Xia, C | 1 |
| Leon-Ferre, R | 1 |
| Laux, D | 1 |
| Deutsch, J | 1 |
| Smith, BJ | 1 |
| Frees, M | 1 |
| Palathinkal, DM | 1 |
| Sharma, TR | 1 |
| Bordeaux, JS | 1 |
| Wei, ZP | 2 |
| Jiang, BS | 1 |
| Speicher, PJ | 1 |
| Thomas, S | 1 |
| Mosca, PJ | 2 |
| Abernethy, AP | 1 |
| Speicher, P | 1 |
| Dolber, PC | 1 |
| Peterson, BL | 2 |
| Sharma, K | 1 |
| Royal, R | 1 |
| Ross, M | 2 |
| Zager, JS | 1 |
| Andersen, MH | 1 |
| Egger, ME | 1 |
| McNally, LR | 1 |
| Nitz, J | 1 |
| McMasters, KM | 2 |
| Gomez-Gutierrez, JG | 1 |
| Cancedda, S | 1 |
| Rohrer Bley, C | 1 |
| Aresu, L | 1 |
| Dacasto, M | 1 |
| Leone, VF | 1 |
| Pizzoni, S | 1 |
| Gracis, M | 1 |
| Marconato, L | 1 |
| Tuominen, R | 1 |
| Jewell, R | 1 |
| van den Oord, JJ | 1 |
| Wolter, P | 1 |
| Stierner, U | 1 |
| Lindholm, C | 1 |
| Lindén, D | 1 |
| Johansson, H | 1 |
| Walker, C | 1 |
| Snowden, H | 1 |
| Newton-Bishop, J | 1 |
| Chen, TC | 1 |
| Cho, HY | 1 |
| Nguyen, J | 1 |
| Jhaveri, N | 1 |
| Rosenstein-Sisson, R | 1 |
| Hofman, FM | 1 |
| Schönthal, AH | 1 |
| O'Kane, GM | 1 |
| Lyons, TG | 1 |
| Colleran, GC | 1 |
| Ahmad, MW | 1 |
| Alken, S | 1 |
| Kavanagh, EC | 1 |
| Fitzpatrick, D | 1 |
| Murray, B | 1 |
| Kelly, CM | 1 |
| Quiros, S | 1 |
| Krumm, A | 1 |
| Merz, S | 1 |
| Switzeny, OJ | 1 |
| Christmann, M | 2 |
| Loquai, C | 2 |
| Linardou, H | 3 |
| Pentheroudakis, G | 1 |
| Varthalitis, I | 1 |
| Gogas, H | 6 |
| Pectasides, D | 2 |
| Makatsoris, T | 1 |
| Fountzilas, G | 5 |
| Bafaloukos, D | 6 |
| Armstrong, JL | 1 |
| Hill, DS | 2 |
| McKee, CS | 1 |
| Hernandez-Tiedra, S | 1 |
| Lorente, M | 1 |
| Lopez-Valero, I | 1 |
| Eleni Anagnostou, M | 1 |
| Babatunde, F | 1 |
| Corazzari, M | 1 |
| Redfern, CPF | 1 |
| Velasco, G | 1 |
| Lovat, PE | 1 |
| Smith, MP | 1 |
| White, R | 1 |
| Barriuso, J | 1 |
| Jones, C | 3 |
| Acosta, JC | 1 |
| Fico, A | 1 |
| Alfano, D | 1 |
| Valentino, A | 1 |
| Vasta, V | 1 |
| Cavalcanti, E | 1 |
| Travali, S | 1 |
| Patriarca, EJ | 1 |
| Caputo, E | 1 |
| Chang, CL | 1 |
| Schabert, VF | 1 |
| Munakata, J | 2 |
| Donga, P | 1 |
| Abhyankar, S | 1 |
| Reyes, CM | 1 |
| Yim, YM | 1 |
| Hamid, O | 2 |
| Daud, A | 2 |
| Falotico, N | 1 |
| Chyla, B | 1 |
| McKeegan, E | 1 |
| Mostafa, NM | 1 |
| Zhu, M | 1 |
| McKee, M | 1 |
| Luo, Y | 3 |
| Giranda, VL | 1 |
| McArthur, GA | 2 |
| Hou, XY | 2 |
| Yang, CS | 2 |
| Liu, WL | 1 |
| Tang, JQ | 1 |
| Ramcharan, R | 1 |
| Aleksic, T | 1 |
| Kamdoum, WP | 1 |
| Gao, S | 1 |
| Pfister, SX | 1 |
| Tanner, J | 1 |
| Bridges, E | 1 |
| Asher, R | 1 |
| Watson, AJ | 5 |
| Woodcock, M | 1 |
| Repapi, E | 1 |
| Li, JL | 1 |
| Macaulay, VM | 1 |
| Hong, DS | 1 |
| Kurzrock, R | 1 |
| Falchook, GS | 1 |
| Andresen, C | 1 |
| Kwak, J | 1 |
| Ren, M | 1 |
| Xu, L | 1 |
| George, GC | 1 |
| Nguyen, LM | 1 |
| O'Brien, JP | 1 |
| Nemunaitis, J | 1 |
| Wilson, MA | 1 |
| Dummer, R | 10 |
| Siano, M | 1 |
| Hunger, RE | 1 |
| Lindenblatt, N | 1 |
| Braun, R | 1 |
| Michielin, O | 3 |
| Mihic-Probst, D | 2 |
| von Moos, R | 3 |
| Najafi, Y | 1 |
| Guckenberger, M | 1 |
| Arnold, A | 1 |
| Piperno-Neumann, S | 2 |
| Diallo, A | 1 |
| Etienne-Grimaldi, MC | 1 |
| Bidard, FC | 1 |
| Rodrigues, M | 1 |
| Plancher, C | 2 |
| Mariani, P | 2 |
| Cassoux, N | 1 |
| Decaudin, D | 2 |
| Asselain, B | 2 |
| Servois, V | 1 |
| Chen, YP | 1 |
| Jiang, XX | 1 |
| Xu, XF | 1 |
| Feng, SX | 1 |
| Beaumont, KA | 1 |
| Daignault, SM | 1 |
| Lui, GYL | 1 |
| Sharp, DM | 1 |
| Gabrielli, B | 1 |
| Weninger, W | 1 |
| Haass, NK | 1 |
| Rocha, CR | 1 |
| Kajitani, GS | 1 |
| Quinet, A | 1 |
| Fortunato, RS | 1 |
| Menck, CF | 1 |
| McQuade, JL | 1 |
| Posada, LP | 1 |
| Lecagoonporn, S | 1 |
| Amaria, RN | 1 |
| Schadendorf, D | 6 |
| Hauschild, A | 4 |
| Robert, C | 3 |
| van den Eertwegh, A | 1 |
| Cranmer, L | 1 |
| O'Day, S | 3 |
| Puzanov, I | 2 |
| Schachter, J | 1 |
| Blank, C | 1 |
| Salama, A | 1 |
| Mehnert, JM | 1 |
| Hille, D | 1 |
| Ebbinghaus, S | 1 |
| Kang, SP | 1 |
| Zhou, W | 1 |
| Ribas, A | 2 |
| Leontovich, AA | 1 |
| Dronca, RS | 2 |
| Nevala, WK | 2 |
| Thompson, MA | 1 |
| Kottschade, LA | 2 |
| Ivanov, LV | 1 |
| Murakami, T | 1 |
| Ling, B | 1 |
| Michel, D | 1 |
| Sakharkar, MK | 1 |
| Yang, J | 2 |
| Ryabaya, OO | 1 |
| Inshakov, AN | 1 |
| Egorova, AV | 1 |
| Emelyanova, MA | 1 |
| Nasedkina, TV | 1 |
| Zasedatelev, AS | 1 |
| Khochenkov, DA | 1 |
| Stepanova, EV | 1 |
| Li, R | 1 |
| Chen, YJ | 1 |
| Hines, DM | 1 |
| Batty, N | 1 |
| Barber, BL | 1 |
| Todeschi, J | 1 |
| Chibbaro, S | 1 |
| Clavier, JB | 1 |
| Lhermitte, B | 1 |
| Goichot, B | 1 |
| Proust, F | 1 |
| Tarhini, AA | 3 |
| Kirkwood, JM | 8 |
| Gooding, WE | 1 |
| Moschos, S | 2 |
| Agarwala, SS | 6 |
| Atkins, MB | 2 |
| Agarwala, S | 2 |
| Logan, T | 1 |
| Clark, JI | 2 |
| Ernstoff, MS | 1 |
| Lawson, D | 1 |
| Dutcher, JP | 1 |
| Weiss, G | 2 |
| Curti, B | 1 |
| Margolin, KA | 2 |
| Plummer, ER | 3 |
| Eustace, AJ | 1 |
| Crown, J | 1 |
| Clynes, M | 1 |
| O'Donovan, N | 1 |
| Quintás-Cardama, A | 1 |
| Lazar, AJ | 1 |
| Kim, K | 1 |
| Triozzi, PL | 1 |
| Aldrich, W | 1 |
| Dombos, C | 1 |
| Camacho, LH | 2 |
| Ng, C | 1 |
| Hernandez, IM | 1 |
| Frost, AM | 1 |
| Jack, MA | 1 |
| Zheng, M | 1 |
| Bocangel, D | 1 |
| Ramesh, R | 1 |
| Ekmekcioglu, S | 1 |
| Poindexter, N | 1 |
| Grimm, EA | 1 |
| Chada, S | 1 |
| Schittek, B | 1 |
| Flaherty, KT | 1 |
| Kulms, D | 1 |
| Maczey, E | 1 |
| Campos, M | 1 |
| Gogel, J | 1 |
| Naumann, SC | 1 |
| Jöst, E | 2 |
| Belohlavek, C | 2 |
| Lennerz, V | 1 |
| Schmidt, CW | 2 |
| Yoo, JS | 5 |
| Potti, A | 1 |
| Yoshimoto, Y | 7 |
| Zipfel, PA | 5 |
| Friedman, HS | 7 |
| Nevins, JR | 1 |
| Ali-Osman, F | 5 |
| Guzel, A | 1 |
| Maciaczyk, J | 1 |
| Dohmen-Scheufler, H | 1 |
| Senturk, S | 1 |
| Volk, B | 1 |
| Ostertag, CB | 1 |
| Nikkhah, G | 1 |
| Boeckmann, L | 3 |
| Thoms, KM | 3 |
| Gutzmer, R | 2 |
| Has, C | 2 |
| Kunz, M | 2 |
| Kuschal, C | 3 |
| Laspe, P | 2 |
| Struever, D | 2 |
| Emmert, S | 3 |
| Baloglu, A | 1 |
| Bezircioglu, I | 1 |
| Cetinkaya, B | 1 |
| Yavuzcan, A | 1 |
| Mathieu, V | 2 |
| Pirker, C | 1 |
| Martin de Lassalle, E | 1 |
| Vernier, M | 1 |
| Mijatovic, T | 1 |
| DeNeve, N | 1 |
| Gaussin, JF | 1 |
| Dehoux, M | 1 |
| Lefranc, F | 2 |
| Berger, W | 1 |
| Kiss, R | 2 |
| Ingold, B | 1 |
| Schraml, P | 2 |
| Heppner, FL | 1 |
| Moch, H | 3 |
| Zaja-Milatovic, S | 1 |
| Thu, YM | 1 |
| Lee, F | 1 |
| Smykla, R | 1 |
| Richmond, A | 3 |
| Kefford, RF | 2 |
| Thomas, NP | 1 |
| Corrie, PG | 1 |
| Palmer, C | 1 |
| Abdi, E | 1 |
| Kotasek, D | 1 |
| Beith, J | 3 |
| Ranson, M | 4 |
| Mortimer, P | 3 |
| McGown, G | 2 |
| Thorncroft, M | 2 |
| Hersey, P | 4 |
| McArthur, G | 1 |
| Davis, ID | 2 |
| Thomson, D | 1 |
| Haydon, A | 2 |
| Kefford, R | 1 |
| Sabharwal, A | 2 |
| Hayward, O | 1 |
| Cubitt, CL | 1 |
| Munster, PN | 1 |
| Yu, H | 1 |
| Sullivan, DM | 1 |
| Jove, R | 1 |
| Messina, JL | 1 |
| Daud, AI | 2 |
| Chen, M | 2 |
| Osman, I | 2 |
| Orlow, SJ | 3 |
| Glass, MR | 1 |
| Rudewicz, P | 1 |
| Vernillet, L | 1 |
| Guenova, E | 1 |
| Lichte, V | 1 |
| Hoetzenecker, W | 1 |
| Woelbing, F | 1 |
| Moehrle, M | 1 |
| Roecken, M | 1 |
| Schaller, M | 1 |
| Subbiah, V | 1 |
| Wolff, JE | 1 |
| Schirmer, M | 1 |
| Rosenberger, A | 1 |
| Schoen, MP | 1 |
| Brockmoeller, J | 1 |
| Siena, S | 1 |
| Crinò, L | 1 |
| Danova, M | 1 |
| Del Prete, S | 1 |
| Cascinu, S | 1 |
| Salvagni, S | 1 |
| Schiavetto, I | 1 |
| Vitali, M | 1 |
| Bajetta, E | 1 |
| Moon, J | 1 |
| Hutchins, LF | 1 |
| Kast, WM | 1 |
| Da Silva, DM | 1 |
| Liu, PY | 1 |
| Thompson, JA | 2 |
| Flaherty, LE | 1 |
| Sondak, VK | 1 |
| Rose, AE | 1 |
| Doudican, N | 1 |
| Yoon, C | 1 |
| McIntyre, S | 1 |
| Alvarado, GC | 1 |
| Caporali, S | 3 |
| Alvino, E | 3 |
| Starace, G | 1 |
| Ciomei, M | 1 |
| Brasca, MG | 1 |
| Levati, L | 3 |
| Garbin, A | 1 |
| Castiglia, D | 2 |
| Covaciu, C | 1 |
| Bonmassar, E | 4 |
| D'Atri, S | 7 |
| Su, Y | 1 |
| Amiri, KI | 2 |
| Horton, LW | 2 |
| Ayers, GD | 1 |
| Koehler, E | 1 |
| Kelley, MC | 1 |
| Schild, SE | 1 |
| Behl, D | 1 |
| Brown, PD | 1 |
| Sande, JR | 1 |
| Deming, RL | 1 |
| Rowland, KM | 1 |
| Bearden, JD | 1 |
| Wierzbicka-Hainaut, E | 1 |
| Mourey, L | 1 |
| Guillot, B | 2 |
| Guillet, G | 1 |
| Tourani, JM | 1 |
| Shah, GD | 1 |
| Socci, ND | 1 |
| Gold, JS | 1 |
| Viale, A | 1 |
| Brady, MS | 1 |
| Coit, DG | 1 |
| Guenterberg, KD | 1 |
| Grignol, VP | 1 |
| Raig, ET | 1 |
| Zimmerer, JM | 1 |
| Chan, AN | 1 |
| Blaskovits, FM | 1 |
| Young, GS | 1 |
| Nuovo, GJ | 1 |
| Mundy, BL | 1 |
| Lesinski, GB | 1 |
| Carson, WE | 1 |
| Angelica Selim, M | 1 |
| Pruitt, SK | 5 |
| Némati, F | 1 |
| Sastre-Garau, X | 1 |
| Laurent, C | 1 |
| Couturier, J | 1 |
| Desjardins, L | 1 |
| Lantz, O | 1 |
| Robert, D | 1 |
| Péguillet, I | 1 |
| Donnadieu, MH | 1 |
| Dahmani, A | 1 |
| Bessard, MA | 1 |
| Gentien, D | 1 |
| Saule, S | 1 |
| Barillot, E | 1 |
| Roman-Roman, S | 1 |
| Jung, SH | 2 |
| Sohn, I | 1 |
| Olson, JA | 1 |
| Kim, C | 1 |
| Lee, CW | 1 |
| Kovacic, L | 1 |
| Klasa, R | 1 |
| Savage, KJ | 1 |
| Thangasamy, T | 1 |
| Sittadjody, S | 1 |
| Mitchell, GC | 1 |
| Mendoza, EE | 1 |
| Radhakrishnan, VM | 1 |
| Limesand, KH | 1 |
| Burd, R | 1 |
| Neyns, B | 1 |
| Tosoni, A | 1 |
| Reardon, DA | 1 |
| Selim, MA | 3 |
| Burchette, J | 1 |
| McMahon, N | 1 |
| Padussis, J | 2 |
| Dianov, GL | 1 |
| Digweed, M | 1 |
| Hassel, JC | 1 |
| Sucker, A | 1 |
| Edler, L | 1 |
| Kurzen, H | 1 |
| Moll, I | 1 |
| Stresemann, C | 1 |
| Spieth, K | 3 |
| Mauch, C | 2 |
| Rass, K | 1 |
| Osmond, GW | 1 |
| Harlan, E | 1 |
| Davis, MD | 1 |
| Pittelkow, MR | 1 |
| Fateh, S | 1 |
| Schell, TD | 1 |
| Gingrich, R | 1 |
| Neves, RI | 1 |
| Drabick, JJ | 1 |
| Zuckerman, JE | 1 |
| Hsueh, T | 1 |
| Koya, RC | 1 |
| Davis, ME | 1 |
| Guida, M | 3 |
| Cramarossa, A | 1 |
| Fistola, E | 1 |
| Porcelli, M | 1 |
| Giudice, G | 1 |
| Lubello, K | 1 |
| Colucci, G | 2 |
| Di Giacomo, AM | 1 |
| Maio, M | 1 |
| Ruffini, F | 3 |
| Muzi, A | 4 |
| Umezawa, K | 1 |
| Graziani, G | 5 |
| Lacal, PM | 5 |
| Movva, S | 1 |
| Verschraegen, CF | 1 |
| Rabinowitz, I | 1 |
| Mangalik, A | 1 |
| Parks, V | 1 |
| Lee, FC | 1 |
| Koreen, L | 1 |
| He, SX | 1 |
| Johnson, MW | 1 |
| Hackel, RE | 1 |
| Khan, NW | 1 |
| Heckenlively, JR | 1 |
| Tentori, L | 4 |
| Dorio, AS | 2 |
| Mazzon, E | 1 |
| Sau, A | 1 |
| Cuzzocrea, S | 1 |
| Vernole, P | 1 |
| Federici, G | 1 |
| Caccuri, AM | 1 |
| Ma, XH | 1 |
| McAfee, QW | 1 |
| Lum, JJ | 1 |
| Li, LZ | 1 |
| Pei, DS | 1 |
| Nickel, AC | 1 |
| Schaefer, A | 1 |
| Schön, MP | 1 |
| Thomale, J | 1 |
| Nagel, G | 1 |
| Fritz, G | 1 |
| Seifert, B | 2 |
| Simcock, M | 2 |
| Goldinger, SM | 1 |
| Gillessen, S | 1 |
| Ochsenbein, A | 2 |
| Cathomas, R | 1 |
| Schläppi, M | 2 |
| Schraml, PH | 1 |
| Mjhic-Probst, D | 1 |
| Mamot, C | 1 |
| Schönewolf, N | 1 |
| Soon, CW | 1 |
| Algazi, AP | 1 |
| Cha, EN | 1 |
| Webb, EM | 1 |
| Kyte, JA | 1 |
| Gaudernack, G | 1 |
| Dueland, S | 1 |
| Trachsel, S | 1 |
| Julsrud, L | 1 |
| Aamdal, S | 1 |
| Patel, PM | 2 |
| Suciu, S | 1 |
| Mortier, L | 1 |
| Kruit, WH | 1 |
| Trefzer, U | 3 |
| Punt, CJ | 1 |
| Davidson, N | 1 |
| Becker, J | 1 |
| Conry, R | 1 |
| Engelen, K | 1 |
| Keilholz, U | 1 |
| Eggermont, AM | 1 |
| Spatz, A | 1 |
| Chiarion-Sileni, V | 1 |
| Romanini, A | 2 |
| Del Bianco, P | 1 |
| Pigozzo, J | 1 |
| Brugnara, S | 1 |
| De Salvo, GL | 1 |
| Handler, MZ | 1 |
| Mruthyunjaya, P | 1 |
| Nelson, K | 1 |
| Boulinguez, S | 1 |
| Schaefer, N | 1 |
| Rasch, K | 1 |
| Moehlenbruch, M | 1 |
| Urbach, H | 1 |
| Stuplich, M | 1 |
| Blasius, E | 1 |
| Scheffler, B | 1 |
| Herrlinger, U | 1 |
| Glas, M | 1 |
| Reuland, SN | 1 |
| Goldstein, NB | 1 |
| Partyka, KA | 1 |
| Cooper, DA | 1 |
| Fujita, M | 3 |
| Norris, DA | 3 |
| Shellman, YG | 1 |
| Puaux, AL | 1 |
| Loumagne, L | 1 |
| Tow, C | 1 |
| Mackay, C | 1 |
| Kato, M | 1 |
| Prévost-Blondel, A | 1 |
| Avril, MF | 1 |
| Nardin, A | 1 |
| Abastado, JP | 1 |
| Craig, EA | 1 |
| Spiegelman, VS | 1 |
| Sosman, J | 2 |
| Larkin, J | 1 |
| Middleton, M | 2 |
| Cantarini, M | 1 |
| Zazulina, V | 1 |
| Kemsley, K | 1 |
| Koprowska, K | 1 |
| Czyż, M | 1 |
| Stark, MS | 1 |
| Woods, SL | 1 |
| Gartside, MG | 1 |
| Bonazzi, VF | 1 |
| Dutton-Regester, K | 1 |
| Aoude, LG | 1 |
| Chow, D | 1 |
| Sereduk, C | 1 |
| Niemi, NM | 1 |
| Tang, N | 1 |
| Ellis, JJ | 1 |
| Reid, J | 1 |
| Zismann, V | 1 |
| Tyagi, S | 1 |
| Muzny, D | 1 |
| Newsham, I | 1 |
| Palmer, JM | 1 |
| Pollak, T | 1 |
| Youngkin, D | 1 |
| Brooks, BR | 1 |
| Lanagan, C | 1 |
| Kobe, B | 1 |
| MacKeigan, JP | 1 |
| Yin, H | 1 |
| Brown, KM | 1 |
| Gibbs, R | 1 |
| Trent, J | 1 |
| Hayward, NK | 1 |
| Devito, N | 1 |
| Yu, M | 1 |
| Chen, R | 1 |
| Pan, E | 1 |
| Huang, ZM | 1 |
| Chinen, M | 1 |
| Chang, PJ | 1 |
| Xie, T | 1 |
| Zhong, L | 1 |
| Demetriou, S | 1 |
| Patel, MP | 1 |
| Scherzer, R | 1 |
| Sviderskaya, EV | 1 |
| Bennett, DC | 1 |
| Millhauser, GL | 1 |
| Oh, DH | 1 |
| Cleaver, JE | 1 |
| Wei, ML | 1 |
| Cheng, Y | 1 |
| Sk, UH | 1 |
| Huber-Keener, KJ | 1 |
| Sun, YW | 1 |
| Amin, S | 1 |
| Sharma, AK | 1 |
| Yang, JM | 1 |
| Segura, PP | 1 |
| Gil, M | 1 |
| Balañá, C | 1 |
| Chacón, I | 1 |
| Langa, JM | 1 |
| Martín, M | 2 |
| Bruna, J | 1 |
| von Teichman, A | 1 |
| Ellis, LZ | 1 |
| Dallaglio, K | 2 |
| Takeda, M | 1 |
| Robinson, WA | 2 |
| Robinson, SE | 2 |
| Lewis, KD | 2 |
| McCarter, MD | 2 |
| Gonzalez, R | 4 |
| Roop, DR | 2 |
| Spritz, RA | 1 |
| Ahn, NG | 1 |
| Trapp, V | 1 |
| Lee, K | 1 |
| Doñate, F | 1 |
| Mazar, AP | 1 |
| Fruehauf, JP | 1 |
| Tatar, Z | 1 |
| Thivat, E | 2 |
| Planchat, E | 1 |
| Gimbergues, P | 2 |
| Gadea, E | 1 |
| Abrial, C | 1 |
| Durando, X | 2 |
| Thompson, DC | 1 |
| Vasiliou, V | 1 |
| Mansard, S | 1 |
| Daste, A | 1 |
| Brocard, L | 1 |
| Magné, N | 1 |
| Suman, VJ | 1 |
| Perez, DG | 2 |
| McWilliams, RR | 1 |
| Kaur, JS | 2 |
| Amatruda, TT | 1 |
| Geoffroy, FJ | 1 |
| Gross, HM | 1 |
| Cohen, PA | 1 |
| Jaslowski, AJ | 1 |
| Kosel, ML | 1 |
| Koekkoek, JA | 1 |
| Wiggenraad, RG | 1 |
| Zwinkels, H | 1 |
| Oosterkamp, HM | 1 |
| Taphoorn, MJ | 1 |
| Oosterkamp, RM | 1 |
| Doudican, NA | 1 |
| Byron, SA | 1 |
| Pollock, PM | 1 |
| Ott, PA | 1 |
| Chang, J | 1 |
| Madden, K | 1 |
| Kannan, R | 1 |
| Muren, C | 1 |
| Escano, C | 1 |
| Cheng, X | 1 |
| Shao, Y | 1 |
| Mendoza, S | 1 |
| Gandhi, A | 1 |
| Liebes, L | 1 |
| Pavlick, AC | 1 |
| Dellinger, RW | 1 |
| Matundan, HH | 1 |
| Ahmed, AS | 1 |
| Duong, PH | 1 |
| Meyskens, FL | 1 |
| Wu, BJ | 1 |
| Li, WP | 1 |
| Qian, C | 1 |
| Ding, W | 1 |
| Zhou, ZW | 1 |
| Jiang, H | 1 |
| Tawbi, HA | 1 |
| Beumer, JH | 1 |
| Buch, SC | 1 |
| Egorin, MJ | 1 |
| Lin, Y | 1 |
| Christner, S | 1 |
| Allred, JB | 1 |
| Lieser, EA | 1 |
| Thompson, M | 1 |
| Maples, WJ | 1 |
| Creagan, ET | 1 |
| Pockaj, BA | 1 |
| Moore, TD | 1 |
| Marchello, BT | 1 |
| Danson, SJ | 1 |
| Thatcher, N | 9 |
| McMurry, TB | 2 |
| McElhinney, RS | 2 |
| Donnelly, DJ | 2 |
| Prignano, F | 1 |
| Coronnello, M | 1 |
| Pimpinelli, N | 1 |
| Cappugi, P | 1 |
| Mini, E | 1 |
| Giannotti, B | 1 |
| Frick, S | 1 |
| Lischner, S | 1 |
| Rosien, F | 1 |
| Haacke, TC | 1 |
| Schäfer, F | 1 |
| Christophers, E | 1 |
| Gollob, JA | 2 |
| McDermott, DF | 1 |
| Tutin, L | 1 |
| Sorokin, P | 1 |
| Parker, RA | 1 |
| Mier, JW | 1 |
| McClay, EF | 1 |
| Conill, C | 5 |
| Puig, S | 5 |
| Toscas, I | 1 |
| Castel, T | 5 |
| Portarena, I | 1 |
| Barbarino, M | 1 |
| Balduzzi, A | 1 |
| Vergati, M | 2 |
| Biroccio, A | 1 |
| Gold, B | 2 |
| Lombardi, ML | 1 |
| Salmaggi, A | 1 |
| Silvani, A | 1 |
| Eoli, M | 1 |
| Lamperti, E | 1 |
| Boiardi, A | 1 |
| Pepponi, R | 4 |
| Marra, G | 2 |
| Fuggetta, MP | 3 |
| Falcinelli, S | 3 |
| Pagani, E | 3 |
| Jiricny, J | 2 |
| Dréno, B | 3 |
| Wallon-Dumont, G | 1 |
| de Gast, GC | 2 |
| Batchelor, D | 1 |
| Kersten, MJ | 1 |
| Vyth-Dreese, FA | 1 |
| Sein, J | 1 |
| van de Kasteele, WF | 1 |
| Nooijen, WJ | 1 |
| Nieweg, OE | 1 |
| de Waal, MA | 1 |
| Boogerd, W | 2 |
| Papadopoulos, N | 1 |
| Plager, C | 1 |
| Eton, O | 1 |
| Ring, S | 1 |
| Prete, SP | 1 |
| Turriziani, M | 2 |
| Bonmassar, L | 1 |
| Passarelli, F | 1 |
| Guadagni, F | 1 |
| Danson, S | 1 |
| Arance, A | 2 |
| Clamp, A | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Krown, SE | 6 |
| Menell, JH | 4 |
| Merrell, J | 2 |
| Lamb, LA | 3 |
| Williams, LJ | 4 |
| Quinn, CJ | 2 |
| Foster, T | 2 |
| Livingston, PO | 5 |
| Houghton, AN | 5 |
| Strauss, SJ | 1 |
| Marples, M | 1 |
| Napier, MP | 1 |
| Meyer, T | 1 |
| Boxall, J | 1 |
| Rustin, GJ | 3 |
| Su, YB | 1 |
| Sohn, S | 1 |
| Quinn, C | 1 |
| Williams, L | 1 |
| Sepkowitz, KA | 1 |
| Kiebert, GM | 1 |
| Jonas, DL | 1 |
| Oubre, DN | 1 |
| Harkness, KA | 1 |
| Manford, MR | 1 |
| Fernández-Ibiza, J | 1 |
| Malvehy, J | 4 |
| Sánchez, M | 3 |
| González-Cao, M | 1 |
| Jorcano, S | 2 |
| Martí, R | 2 |
| Treudler, R | 1 |
| Georgieva, J | 1 |
| Geilen, CC | 1 |
| Orfanos, CE | 1 |
| Dvorak, J | 1 |
| Melichar, B | 1 |
| Zizka, J | 1 |
| Hadzi-Nikolov, D | 1 |
| Petera, J | 1 |
| Gore, M | 1 |
| Czarnetski, B | 1 |
| Atkins, M | 1 |
| Buzaid, A | 1 |
| Skarlos, D | 3 |
| Rankin, EM | 1 |
| Lanzilli, G | 1 |
| Tricarico, M | 1 |
| Cannavò, E | 1 |
| Zambruno, G | 2 |
| Falchetti, R | 1 |
| Ravagnan, G | 1 |
| LaFleur, BJ | 1 |
| Richtig, E | 1 |
| Hofmann-Wellenhof, R | 1 |
| Pehamberger, H | 1 |
| Forstinger, Ch | 1 |
| Wolff, K | 1 |
| Mischer, P | 1 |
| Raml, J | 1 |
| Fritsch, P | 1 |
| Zelger, B | 1 |
| Ratzinger, G | 1 |
| Koller, J | 1 |
| Lang, A | 1 |
| Konrad, K | 1 |
| Kindermann-Glebowski, E | 1 |
| Seeber, A | 1 |
| Steiner, A | 1 |
| Fialla, R | 1 |
| Pachinger, W | 1 |
| Kos, C | 1 |
| Klein, G | 1 |
| Kehrer, H | 1 |
| Kerl, H | 1 |
| Ulmer, H | 1 |
| Smolle, J | 1 |
| Tsoutsos, D | 3 |
| Christodoulou, C | 3 |
| Kalofonos, HP | 1 |
| Briassoulis, E | 3 |
| Panagiotou, P | 3 |
| Hatzichristou, H | 1 |
| Sileni, VC | 1 |
| Michiara, M | 1 |
| Biasco, G | 3 |
| Poletti, P | 1 |
| Amaducci, L | 1 |
| Leoni, M | 1 |
| Ravaioli, A | 1 |
| Ueno, T | 2 |
| Ko, SH | 2 |
| Grubbs, E | 2 |
| Harting, MS | 1 |
| Buzaid, AC | 2 |
| Aravantinos, G | 1 |
| Bamias, A | 1 |
| Carina, M | 1 |
| Klouvas, G | 1 |
| Azzabi, A | 1 |
| Hughes, AN | 1 |
| Calvert, PM | 1 |
| Todd, R | 1 |
| Griffin, MJ | 1 |
| Lind, MJ | 2 |
| Maraveyas, A | 1 |
| Kelly, C | 1 |
| Fishwick, K | 1 |
| Calvert, AH | 5 |
| Boddy, AV | 2 |
| Panagiotou, IE | 1 |
| Brountzos, EN | 1 |
| Kelekis, DA | 1 |
| Papathanasiou, MA | 1 |
| Bafaloukos, DI | 1 |
| Kalofonos, H | 1 |
| Chalkidou, S | 1 |
| Linardou, E | 1 |
| Efstathiou, E | 1 |
| Polyzos, A | 2 |
| Kouroussis, C | 1 |
| Iconomou, T | 1 |
| Lis, E | 2 |
| Olsen, A | 1 |
| Hickson, I | 1 |
| McHugh, P | 1 |
| Harris, AL | 1 |
| Newell, DR | 2 |
| Curtin, NJ | 1 |
| Poggi, R | 1 |
| Pantaleo, MA | 2 |
| Benedetti, G | 1 |
| Passagne, I | 1 |
| Evrard, A | 1 |
| Depeille, P | 1 |
| Cuq, P | 1 |
| Vian, L | 1 |
| Gibbs, P | 1 |
| Richards, J | 2 |
| Weber, J | 2 |
| Anderson, C | 1 |
| Baron, A | 1 |
| Russ, P | 1 |
| Hofmann, M | 1 |
| Kiecker, F | 1 |
| Wurm, R | 1 |
| Schlenger, L | 1 |
| Budach, V | 1 |
| Sterry, W | 1 |
| Koch, HJ | 1 |
| Roeber, S | 1 |
| Zimmermann, UW | 1 |
| Schäfer, C | 1 |
| Villarrubia, V | 1 |
| Kuchelmeister, K | 1 |
| Schachenmayr, W | 1 |
| Bogdahn, U | 1 |
| Steinbrecher, A | 1 |
| Ready, N | 1 |
| Aronson, F | 1 |
| Wanebo, H | 1 |
| Kennedy, T | 1 |
| Narita, Y | 1 |
| Minor, DR | 1 |
| Madland, MT | 1 |
| Kashani-Sabet, M | 1 |
| Denny, SR | 1 |
| Harvey, WB | 1 |
| Weber, RW | 1 |
| Rose, M | 1 |
| Deck, R | 1 |
| Ames, P | 1 |
| Good, J | 1 |
| Meyer, J | 1 |
| Allen, R | 1 |
| Trautvetter, S | 1 |
| Timmerman, M | 1 |
| Cruickshank, S | 1 |
| Cook, M | 1 |
| Spitler, LE | 1 |
| Kaufmann, R | 2 |
| von den Driesch, P | 1 |
| Vogt, T | 2 |
| Linse, R | 2 |
| Tilgen, W | 3 |
| Becker, JC | 2 |
| Sebastian, G | 1 |
| Krengel, S | 1 |
| Kretschmer, L | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| Forini, O | 1 |
| Argon, A | 1 |
| Camlica, H | 2 |
| Topuz, E | 2 |
| Mori, T | 1 |
| O'Day, SJ | 1 |
| Umetani, N | 1 |
| Martinez, SR | 1 |
| Kitago, M | 1 |
| Koyanagi, K | 1 |
| Kuo, C | 1 |
| Takeshima, TL | 1 |
| Milford, R | 1 |
| Wang, HJ | 1 |
| Vu, VD | 1 |
| Nguyen, SL | 1 |
| Hoon, DS | 1 |
| Suppasansatorn, P | 2 |
| Wang, G | 1 |
| Conway, BR | 2 |
| González Cao, M | 1 |
| Carrera, C | 1 |
| Herrero, J | 1 |
| Gascón, P | 1 |
| Mellado, B | 1 |
| Ron, IG | 1 |
| Sarid, D | 1 |
| Ryvo, L | 1 |
| Sapir, EE | 1 |
| Schneebaum, S | 1 |
| Metser, U | 1 |
| Asna, N | 1 |
| Inbar, MJ | 1 |
| Safra, T | 1 |
| Kundranda, MN | 1 |
| Clark, CT | 1 |
| Chaudhry, AA | 1 |
| Chan, V | 1 |
| Daw, HA | 1 |
| Augustine, C | 1 |
| Abdel-Wahab, Z | 1 |
| Cheng, TY | 1 |
| Abdel-Wahab, OI | 1 |
| Aird, S | 1 |
| Domingo-Doménech, J | 1 |
| Gallego, R | 1 |
| Vilella, R | 1 |
| Laber, DA | 1 |
| Okeke, RI | 1 |
| Arce-Lara, C | 1 |
| Taft, BS | 1 |
| Schonard, CL | 1 |
| Kloecker, GH | 1 |
| Miller, DM | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Trechot, P | 1 |
| Masucci, GV | 1 |
| Månsson-Brahme, E | 1 |
| Ragnarsson-Olding, B | 1 |
| Nilsson, B | 1 |
| Wagenius, G | 1 |
| García, M | 1 |
| del Muro, XG | 1 |
| Tres, A | 1 |
| Crespo, C | 1 |
| Valladares, M | 1 |
| López, JJ | 1 |
| Rifà, J | 1 |
| Pérez, X | 1 |
| Filipovich, E | 1 |
| Germà-Lluch, JR | 1 |
| Caporaso, P | 2 |
| Fischer, F | 1 |
| Stavrinidis, I | 1 |
| Frangia, K | 1 |
| Markopoulos, C | 1 |
| Papadopoulos, O | 1 |
| Mantzourani, M | 1 |
| Vaiopoulos, G | 1 |
| Niedzwiecki, D | 1 |
| Hodgson, L | 1 |
| Haluska, FG | 1 |
| Ugurel, S | 2 |
| Thoelke, A | 1 |
| Egberts, F | 1 |
| Kreissig, M | 1 |
| Mohr, P | 1 |
| Larkin, JM | 1 |
| Hughes, SA | 1 |
| Beirne, DA | 1 |
| Gibbens, IM | 1 |
| Bate, SC | 1 |
| Thomas, K | 1 |
| Eisen, TG | 1 |
| Gore, ME | 1 |
| Dalesio, O | 1 |
| Le Mercier, M | 1 |
| De Neve, N | 1 |
| Sauvage, S | 1 |
| Gras, T | 1 |
| Roland, I | 1 |
| Thompson, D | 1 |
| Harris, PA | 1 |
| Baka, S | 1 |
| Seebaran, A | 1 |
| Weller, M | 1 |
| Kouvaris, JR | 1 |
| Miliadou, A | 1 |
| Kouloulias, VE | 1 |
| Kolokouris, D | 1 |
| Balafouta, MJ | 1 |
| Papacharalampous, XN | 1 |
| Vlahos, LJ | 1 |
| Majer, M | 1 |
| Jensen, RL | 1 |
| Shrieve, DC | 1 |
| Watson, GA | 1 |
| Wang, M | 1 |
| Leachman, SA | 1 |
| Boucher, KM | 1 |
| Samlowski, WE | 1 |
| Nimmannit, U | 1 |
| Quirin, C | 1 |
| Mainka, A | 1 |
| Hesse, A | 1 |
| Nettelbeck, DM | 1 |
| Sawrie, SM | 1 |
| Guthrie, BL | 1 |
| Spencer, SA | 1 |
| Nordal, RA | 1 |
| Meredith, RF | 1 |
| Markert, JM | 1 |
| Cloud, GA | 1 |
| Fiveash, JB | 1 |
| Quirt, I | 1 |
| Verma, S | 1 |
| Petrella, T | 1 |
| Bak, K | 1 |
| Charette, M | 1 |
| Fontijn, D | 1 |
| Adema, AD | 1 |
| Bhakat, KK | 1 |
| Pinedo, HM | 1 |
| Peters, GJ | 1 |
| Boven, E | 1 |
| Mhaidat, NM | 1 |
| Zhang, XD | 1 |
| Allen, J | 1 |
| Avery-Kiejda, KA | 1 |
| Scott, RJ | 1 |
| Beyeler, M | 1 |
| Bröcker, EB | 1 |
| Kaehler, KC | 1 |
| Pföhler, C | 1 |
| Gille, J | 1 |
| Testori, A | 1 |
| Whitman, E | 1 |
| Mann, GB | 1 |
| Camacho, L | 1 |
| Parmiani, G | 1 |
| Tosti, G | 1 |
| Hoos, A | 1 |
| Yuh, L | 1 |
| Gupta, R | 1 |
| Srivastava, PK | 1 |
| Pick, AM | 1 |
| Neff, WJ | 1 |
| Nystrom, KK | 1 |
| Khamari, A | 1 |
| Delaunay, M | 1 |
| Picot, MC | 1 |
| Dereure, O | 1 |
| Bael, TE | 1 |
| Navarra, P | 1 |
| Mandic, M | 1 |
| Storkus, WJ | 1 |
| Lotze, MT | 1 |
| Dehart, WK | 1 |
| Gilliam, AC | 1 |
| Lu, KQ | 1 |
| Brell, J | 1 |
| Rietschel, P | 1 |
| Krown, S | 1 |
| Gerst, S | 1 |
| Jungbluth, AA | 1 |
| Busam, K | 1 |
| Smith, K | 1 |
| Orlow, I | 1 |
| Panageas, K | 1 |
| Gupta, M | 1 |
| Febbo, P | 1 |
| Pendergast, AM | 1 |
| Peters, WP | 1 |
| Bleehen, NM | 2 |
| Newlands, ES | 4 |
| Lee, SM | 4 |
| Selby, P | 1 |
| Brampton, M | 1 |
| Stevens, MF | 3 |
| Crowther, D | 1 |
| Belanich, M | 2 |
| Randall, T | 1 |
| Pastor, MA | 1 |
| Kibitel, JT | 1 |
| Alas, LG | 1 |
| Dolan, ME | 1 |
| Schold, SC | 1 |
| Gander, M | 3 |
| Lejeune, FJ | 1 |
| Li, BF | 1 |
| White, AB | 1 |
| Wasserman, P | 1 |
| Citron, ML | 1 |
| Yarosh, DB | 1 |
| Anderson, CM | 1 |
| Legha, SS | 1 |
| Marzolini, C | 2 |
| Decosterd, LA | 1 |
| Shen, F | 2 |
| Leyvraz, S | 2 |
| Buclin, T | 1 |
| Biollaz, J | 2 |
| Lejeune, F | 2 |
| Lunn, JM | 1 |
| Morris, C | 1 |
| Rustin, G | 2 |
| Wedge, SR | 1 |
| Brampton, MH | 3 |
| Decosterd, L | 1 |
| Bonfanti, M | 1 |
| Liénard, D | 1 |
| Perey, L | 1 |
| Colella, G | 1 |
| Yarosh, D | 1 |
| D'Incalci, M | 1 |
| Brada, M | 1 |
| Judson, I | 1 |
| Beale, P | 1 |
| Moore, S | 1 |
| Reidenberg, P | 1 |
| Statkevich, P | 1 |
| Dugan, M | 1 |
| Batra, V | 1 |
| Cutler, D | 1 |
| Kelly, J | 1 |
| McCormick, JE | 1 |
| Hillner, BE | 1 |
| Cohen, MH | 1 |
| Johnson, JR | 1 |
| Kerby, T | 1 |
| Wood, M | 1 |
| Burg, G | 1 |
| Casadei, S | 1 |
| Georgoulias, V | 1 |
| Samantas, E | 1 |
| Kalofonos, Ch | 1 |
| Karabelis, A | 1 |
| Kosmidis, P | 1 |
| Raizer, J | 1 |
| Paul, MJ | 1 |
| Summers, Y | 1 |
| Margolin, K | 1 |
| Atkins, B | 1 |
| Thompson, A | 1 |
| Ernstoff, S | 1 |
| Flaherty, L | 1 |
| Clark, I | 1 |
| II Smith, W | 1 |
| Dutcher, P | 1 |
| Gollob, J | 1 |
| Longmate, J | 1 |
| Johnson, D | 1 |
| Blackledge, GR | 1 |
| Slack, JA | 1 |
| Smith, DB | 1 |
| Stuart, NS | 1 |
| Quarterman, CP | 1 |
| Hoffman, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2 Study of Apatinib Combined With Temozolomide in the Treatment of Advanced Melanoma Patients After Conventional Treatment Failure[NCT03422445] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | ||
| A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma[NCT02023710] | Phase 2 | 182 participants (Anticipated) | Interventional | 2013-12-31 | Recruiting | ||
| Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma[NCT01143402] | Phase 2 | 120 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| Phase Ib/II: Epigenetic Modification of Chemosensitivity and Apoptosis in Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine, Temozolomide and Panobinostat[NCT00925132] | Phase 1/Phase 2 | 39 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to Change in the number of approved drugs for metastatic melanoma) | ||
| A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era[NCT03138642] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-07-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma[NCT00804908] | Phase 2 | 346 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients With Advanced Melanoma (KEYNOTE 002)[NCT01704287] | Phase 2 | 540 participants (Actual) | Interventional | 2012-11-20 | Completed | ||
| Multicenter Phase 2 Evaluation of Temozolomide for Treatment of Brain Metastases of Either Malignant Melanoma, Breast and Non-small Cell Lung Cancer.[NCT00831545] | Phase 2 | 162 participants (Actual) | Interventional | 2000-12-01 | Completed | ||
| A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma[NCT00104988] | Phase 2 | 64 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Phase I Study of the Combination of Axitinib (AX) Plus Everolimus (EV) in Patients With Malignant Advanced Solid Tumors[NCT01334073] | Phase 1 | 19 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Systemic Temozolomide Treatment Of Melanoma Present In The Central Nervous System[NCT00068666] | Phase 2 | 41 participants (Actual) | Interventional | 2004-01-31 | Terminated | ||
| A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases.[NCT02036086] | Phase 2 | 24 participants (Actual) | Interventional | 2015-08-31 | Active, not recruiting | ||
| Temozolomide Combined With Bevacizumab in Metastatic Melanoma. A Multicenter Phase II Trial[NCT00568048] | Phase 2 | 62 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group[NCT00091572] | Phase 3 | 859 participants (Actual) | Interventional | 2004-10-20 | Completed | ||
| Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Rand[NCT00005052] | Phase 3 | 0 participants | Interventional | 1999-12-31 | Active, not recruiting | ||
| A Randomized Phase II Trial of Temozolomide (TMZ) and Bevacizumab or ABI-007 (ABX)/Carboplatin (CBDCA) and Bevacizumab in Patients With Unresectable Stage IV Malignant Melanoma[NCT00626405] | Phase 2 | 95 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma[NCT00521001] | Phase 2 | 49 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer[NCT06017284] | Phase 3 | 100 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma[NCT00005815] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-12-31 | Completed | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Treatment of Patients With Metastatic Malignant Melanoma With Chemobiotherapy With Temozolomide, GM-CSF, IL2, and Interferon Alfa-2b Phase II Trial[NCT00014092] | Phase 2 | 0 participants | Interventional | 1999-12-31 | Completed | ||
| Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation[NCT01959633] | Phase 1/Phase 2 | 11 participants (Actual) | Interventional | 2014-04-03 | Completed | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary analysis will be performed among the Gnaq/Gna11 mutant patients. A stratified logrank test will be performed stratified by mutation status, M stage, and number of prior systemic therapies for metastatic disease. Due to the potential for a large number of strata and small strata sizes, the standard asymptotic stratified logrank test will be verified for robustness utilizing a permutation reference distribution. (NCT01143402)
Timeframe: The time from randomization to death due to any cause, assessed up to 5 years
| Intervention | Months (Median) |
|---|---|
| Arm I (Temozolomide) | 9.1 |
| Arm II (Selumetinib) | 11.8 |
The primary analysis will be performed among the Gnaq/Gna11 mutant patients. A stratified logrank test will be performed stratified by mutation status, M stage, and number of prior systemic therapies for metastatic disease. Due to the potential for a large number of strata and small strata sizes, the standard asymptotic stratified logrank test will be verified for robustness utilizing a permutation reference distribution. (NCT01143402)
Timeframe: The time from randomization to the earlier date of objective disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria or death due to any cause in the absence of progression, assessed up to 5 years
| Intervention | weeks (Median) |
|---|---|
| Arm I (Temozolomide) | 7 |
| Arm II (Selumetinib) | 15.9 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
"Tumor response rate was assessed using RECIST criteria in which a complete response was the disappearance of all target lesions; Partial response was a 30% decrease in the sum of the longest dimension (LD) of target lesions, relative to baseline measurement; Progressive disease was an increase of 20% or more in the sum of the LD of target lesions; and Stable disease was a decrease in tumor size of less than 30% or increase of less than 20%.~Tumor response rate was also assessed using CHOI's criteria in which a response was a 10% decrease in tumor size or a 15% decrease in tumor density on contrast-enhanced computed tomography scan.~Tumor response rates were assessed in order to determine effectiveness of the treatment regimen which was defined by the response rate of at least 30% as measured by either the RECIST or Choi's criteria, and ineffective if the rate is less than 15% on both." (NCT00925132)
Timeframe: 12 weeks (2 cycles)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | |
| Phase II:Decitabine 0.2 mg/kg +Panobinostat 30mg +Temozolomide | 12 | 5 |
"A DLT was any Grade 4 toxicity for neutrophils or platelets for ≥ 7 days, Grade 3 toxicity for neutrophils for ≥ 21 days, any Grade 3 solid organ toxicity not explainable by another cause (e.g. neurotoxicity, GI toxicity), metabolic/laboratory toxicity (≥10 x ULN AST) for ≥ 14 days, any Grade 4 infection or QTcF> 500msec EKG. DLTs were assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0.~All adverse events were collected and graded to determine DLTs as assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0. DLTs were assessed to determine the recommended Decitabine and Panobinostat dose for the Phase II portion of the trial." (NCT00925132)
Timeframe: 6 weeks (one full cycle)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Cohort 1: Experienced DLT | Cohort 2: Experienced DLT | Cohort 3: Experienced DLT | Cohort 4: Experienced DLT | |
| Phase I Dose Escalation | 0 | 0 | 0 | 0 |
The 12-month overall survival rate was defined as the percentage of participants surviving at 12 months. The distribution of 12-month OS rate was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Per protocol, survival was to be assessed every 4 weeks or as needed after participant is registered as off-study for up to 18 months. The maximum observed follow-up at the overall survival analysis time was 21.0 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 52.6 |
| ABT-888 20 mg BID + TMZ QD | 43.5 |
| ABT-888 40 mg BID + TMZ QD | 54.1 |
The 6-month progression-free survival rate was defined as the percentage of participants without disease progression at 6 months.The distribution of 6-month progression-free survival rate, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 19.1 |
| ABT-888 20 mg BID + TMZ QD | 32.8 |
| ABT-888 40 mg BID + TMZ QD | 30.7 |
The disease control rate was defined as the percentage of participants who had at least stable disease (complete response, partial response, or stable disease) through the end of Week 8. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 48.7 |
| ABT-888 20 mg BID + TMZ QD | 62.9 |
| ABT-888 40 mg BID + TMZ QD | 59.1 |
The objective response rate was defined as the percentage of participants with a confirmed CR or PR per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by computed tomography (CT) scan: complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo for ABT-888 BID + TMZ QD | 7.0 |
| ABT-888 20 mg BID + TMZ QD | 10.3 |
| ABT-888 40 mg BID + TMZ QD | 9.6 |
OS was defined as the number of days from the date the participant was randomized to the date of death. All deaths were included, whether the participant was still taking or had discontinued study drug. If a participant had not died and was lost to follow-up, then data were censored at the last study visit or contact date, or date the participant was last known to be alive, whichever was later; if the participant was not lost to follow-up, then data were censored at the last study visit or contact date, whichever was later. The distribution of OS was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the OS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints. (NCT00804908)
Timeframe: Per protocol, survival follow-up information was to be obtained every 3 months for up to 18 months after the final visit for the subject. The maximum observed follow-up at the overall survival analysis time was 21.0 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 204 | 327 | NA |
| ABT-888 40 mg BID + TMZ QD | 181 | 412 | NA |
| Placebo for ABT-888 BID + TMZ QD | 207 | 390 | 559 |
PFS: the number of days from the date that the participant was randomized to the date the participant experienced a confirmed event of disease progression (radiological, as determined by the central imaging center; or clinical, as determined by the investigator), or to the date of death (all causes of mortality) if disease progression was not reached. All events were included whether the participant was still taking or had discontinued study drug. Events of death were included for participants who had not experienced a confirmed event of disease progression, provided the death occurred within 8 weeks of the last available disease progression assessment. The distribution of PFS, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% confidence intervals (95% CIs) for the quartiles for the PFS distribution are provided. (NCT00804908)
Timeframe: Every Cycle (28 Days) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th Percentile | 75th Percentile | |
| ABT-888 20 mg BID + TMZ QD | 56 | 113 | 225 |
| ABT-888 40 mg BID + TMZ QD | 53 | 110 | 226 |
| Placebo for ABT-888 BID + TMZ QD | 54 | 60 | 163 |
The distribution of time to disease progression, as determined by the central imaging center (radiological)/ investigator (clinical), was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the PFS distribution are provided. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ treatment groups were statistically significantly better than the Placebo + TMZ treatment group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every Cycle (28 Days), until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 56 | 113 | 225 |
| ABT-888 40 mg BID + TMZ QD | 53 | 110 | 226 |
| Placebo for ABT-888 BID + TMZ QD | 54 | 60 | 163 |
Time to neurological/brain metastases progression, defined as the number of days from the date of randomization to the date the participant experienced an event of neurological/brain metastases progression, was estimated using Kaplan-Meier methodology. Point estimates and 95% CIs for the quartiles for the distribution are provided. All events of progression were included, regardless of whether the event occurred while the participant was still taking study drug. If a participant did not experience an event, data were censored at the date of the last available brain CT scan. For participants with no postbaseline brain CT scans, data were censored at randomization. Per protocol, because neither the ABT-888 20 mg BID + TMZ nor ABT-888 40 mg BID + TMZ groups were statistically significantly better than the Placebo + TMZ group for the primary endpoint of PFS, confirmatory statistical testing was not continued for any secondary endpoints, regardless of the observed P values. (NCT00804908)
Timeframe: Every 2 cycles (8 weeks) until disease progression was observed or another reason for discontinuation of assessments was identified by the investigator. The maximum observed followup duration at the progression-free survival analysis time was 9.7 months.
| Intervention | days (Number) | ||
|---|---|---|---|
| 25th Percentile | 50th percentile | 75th percentile | |
| ABT-888 20 mg BID + TMZ QD | 119 | NA | NA |
| ABT-888 40 mg BID + TMZ QD | 184 | 184 | NA |
| Placebo for ABT-888 BID + TMZ QD | 60 | NA | NA |
For participants who demonstrated a confirmed response (Complete Response [CR]: disappearance of all target lesions or Partial Response [PR]: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of CR or PR until disease progression or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. DOR analysis was based on IRO assessment. Analysis of DOR was not planned or analyzed for the switch-to-pembrolizumab treatment groups. Median DOR for participants who demonstrated a confirmed response is presented. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 22.8 |
| Pembrolizumab 10 mg/kg | NA |
| Investigator-Choice Chemotherapy (ICC) | 6.8 |
OS was defined as the time from randomization to death due to any cause. Analysis of OS was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median OS duration based on the product-limit (Kaplan-Meier) method for censored data is presented. This was the final analysis for OS. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 13.4 |
| Pembrolizumab 10 mg/kg | 14.7 |
| Investigator-Choice Chemotherapy (ICC) | 11.0 |
OS was defined as the time from randomization to death due to any cause. Analysis of OS was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median OS based on the product-limit (Kaplan-Meier) method for censored data is presented. This was the interim analysis for OS. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 13.4 |
| Pembrolizumab 10 mg/kg | 14.7 |
| Investigator-Choice Chemotherapy (ICC) | 11.0 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of study drug, was also an AE. The number of participants who discontinued study drug due to an AE is presented. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab 2 mg/kg | 29 |
| Pembrolizumab 10 mg/kg | 33 |
| ICC Only | 13 |
| ICC→Pembrolizumab 2 mg/kg | 1 |
| ICC→Pembrolizumab 10 mg/kg | 1 |
| ICC→Pembrolizumab 2 mg/kg (After Switch to Pembrolizumab) | 4 |
| ICC→Pembrolizumab 10 mg/kg (After Switch to Pembrolizumab) | 4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which was temporally associated with the use of study drug, was also an AE. Participants were included in the treatment group in which an AE was experienced. The number of participants who experienced at least one AE is presented. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab 2 mg/kg | 172 |
| Pembrolizumab 10 mg/kg | 179 |
| ICC Only | 71 |
| ICC→Pembrolizumab 2 mg/kg | 52 |
| ICC→Pembrolizumab 10 mg/kg | 45 |
| ICC→Pembrolizumab 2 mg/kg (After Switch to Pembrolizumab) | 53 |
| ICC→Pembrolizumab 10 mg/kg (After Switch to Pembrolizumab) | 41 |
ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. Analysis of ORR was not planned or conducted for the switch-to-pembrolizumab treatment groups. The percentage of participants who experienced a CR or PR is presented. This was the final analysis for ORR. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab 2 mg/kg | 22.2 |
| Pembrolizumab 10 mg/kg | 27.6 |
| Investigator-Choice Chemotherapy (ICC) | 4.5 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Criteria in Solid Tumors version 1.1 (RECIST 1.1), PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. Note: The appearance of one or more new lesions was also considered PD. Analysis of PFS was based on an integrated radiology and oncology (IRO) assessment and was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median PFS based on the product limit (Kaplan-Meier) method for censored data is presented. This was the final analysis for PFS. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab 2 mg/kg | 2.9 |
| Pembrolizumab 10 mg/kg | 3.0 |
| Investigator-Choice Chemotherapy (ICC) | 2.8 |
BOR was assessed by independent radiology review using RECIST 1.1 and was recorded from randomization until the last imaging assessment in this period. Response categories included: Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions; and Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. BOR for the Initial Treatment Period was based on IRO. BOR for participants during the Initial Treatment Period is presented. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Percentage of Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | No Disease | No Assessment | |
| Investigator-Choice Chemotherapy (ICC) | 0.0 | 4.5 | 19.0 | 61.5 | 15.1 | 0.0 | 0.0 |
| Pembrolizumab 10 mg/kg | 7.2 | 20.4 | 14.9 | 47.5 | 9.9 | 0.0 | 0.0 |
| Pembrolizumab 2 mg/kg | 3.3 | 18.9 | 16.7 | 46.7 | 13.3 | 0.6 | 0.6 |
The BOR was assessed using RECIST 1.1 and was recorded from the start of the second line of study drug (pembrolizumab) until the last imaging assessment in this period. Response categories included: Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions; and Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For the switch-to-pembrolizumab treatment groups, BOR was based on independent review committee (IRC) assessment. The BOR for switched-to pembrolizumab treatment groups is presented. (NCT01704287)
Timeframe: Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | No Assessment | |
| ICC→Pembrolizumab 10 mg/kg | 4.4 | 13.3 | 11.1 | 55.6 | 13.3 | 2.2 |
| ICC→Pembrolizumab 2 mg/kg | 1.9 | 17.0 | 15.1 | 54.7 | 11.3 | 0.0 |
OS was defined as the time from randomization to death due to any cause. Participants with an Allred Proportion Score (APS) ≥2 (membranous staining in ≥1% of cells for PD-L1) were considered to be PD-L1 Positive and participants with an APS of 0 or 1 were considered to be PD-L1 Negative. Analysis of OS was not planned or conducted for the switch-to-pembrolizumab treatment groups. Median OS duration based on the product-limit (Kaplan-Meier) method for censored data by PD-L1 tumor expression status is presented. (NCT01704287)
Timeframe: Up to approximately 75 months (Through End of Trial Analysis database cutoff date of 31-Jan-2019)
| Intervention | Months (Median) | |
|---|---|---|
| PD-L1 Positive | PD-L1 Negative | |
| Investigator-Choice Chemotherapy (ICC) | 12.1 | 9.3 |
| Pembrolizumab 10 mg/kg | 17.5 | 13.4 |
| Pembrolizumab 2 mg/kg | 15.0 | 10.5 |
Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented. (NCT00091572)
Timeframe: Treatment continued until disease progression or unacceptable toxicity.
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 4.34 |
| Dacarbazine | 8.31 |
Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter. (NCT00091572)
Timeframe: Treatment continued until disease progression or unacceptable toxicity.
| Intervention | Ratio (Median) |
|---|---|
| Temozolomide | 0.14 |
| Dacarbazine | 0.10 |
Overall Survival was defined as the time from the date of randomization to the date of death from any cause. (NCT00091572)
Timeframe: The final analysis was to be performed when at least 616 deaths had occurred.
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 9.13 |
| Dacarbazine | 9.36 |
Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause. (NCT00091572)
Timeframe: Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 2.30 |
| Dacarbazine | 2.17 |
Overall survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT00626405)
Timeframe: Up to 5 years
| Intervention | Months (Median) |
|---|---|
| Arm I | 12.3 |
| Arm II | 13.9 |
The primary endpoint is the 6 month post registration Progression-free survival (PFS) rate. Progression-free survival time is defined as the time from registration to documentation of disease progression using the RECIST criteria. Patients who died without documentation of disease progression will be considered to have progressed at death unless there is sufficient documented evidence to conclude no progression occurred prior to death. All patients, who meet the eligibility criteria, sign a consent form, and start treatment will be included in the evaluation of the 6 month PFS rate. (NCT00626405)
Timeframe: at 6 months
| Intervention | % of patients alive and progression free (Number) |
|---|---|
| Arm I | 32.8 |
| Arm II | 56.1 |
"A confirmed tumor response is defined to be a Complete Response or Partial Response noted~> as the objective status on 2 consecutive evaluations at least 8~> weeks apart. The proportion of tumor responses will be~> estimated by the number of confirmed tumor responses divided~> by the total number of evaluable patients.~> Complete Response (CR): Disappearance of all target lesions~> Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.~> Progression (PD): At least a 20% increase in the sum of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.~> Stable Disease (SD): Neither sufficient shrinkage to Qualify for PR nor sufficient increase to Qualify for PD taking as reference the smallest sum LD. responses will be calculated assuming that the number of~> confirmed tumor responses follows a binomial distribution." (NCT00626405)
Timeframe: Up to 5 years
| Intervention | percentage of patients with response (Number) |
|---|---|
| Arm I | 23.8 |
| Arm II | 33.3 |
The primary endpoint of this trial is the 9 week PFS rate. A patient is a success if they are progression free at their cycle 2 evaluation (approximately 9 weeks post registration). All patients, who meet the eligibility criteria, sign a consent form, and start treatment will be included in the evaluation of the 9-week PFS rate (evaluable patients). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated using the properties of the binomial distribution. If some patients are lost to follow up prior to their cycle 2 evaluation, the Kaplan-Meier method will be used to estimate the 9 week PFS rate. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00521001)
Timeframe: at 9 weeks
| Intervention | proportion of patients (Number) |
|---|---|
| Everolimus + Temozolomide | 0.44 |
Confirmed response rates will be evaluated by dividing the number of confirmed responders (i.e. patients that achieve a CR or PR on consecutive evaluations) by the total number of evaluable patients. Confidence intervals for the true response rate will be calculated using the properties of the binomial distribution. (NCT00521001)
Timeframe: Up to 5 years
| Intervention | percentage of confirmed responses (Number) |
|---|---|
| Everolimus + Temozolomide | 8.3 |
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT00521001)
Timeframe: Time from registration to death due to any cause; Up to 5 years
| Intervention | months (Median) |
|---|---|
| Everolimus + Temozolomide | 8.6 |
Time to disease progression is defined as the time from registration to the earliest date documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of time to progression will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00521001)
Timeframe: Time from registration to the earliest date documentation of disease progression; Up to 5 years
| Intervention | months (Median) |
|---|---|
| Everolimus + Temozolomide | 2.4 |
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
38 reviews available for temozolomide and Melanoma
| Article | Year |
|---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; | 2021 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; | 2021 |
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; | 2021 |
Plasmas for Treating Cancer: Opportunities for Adaptive and Self-Adaptive Approaches.
Topics: Animals; Antineoplastic Agents, Alkylating; Aquaporins; Cell Line, Tumor; Drug Resistance, Neoplasm; | 2018 |
Plasmas for Treating Cancer: Opportunities for Adaptive and Self-Adaptive Approaches.
Topics: Animals; Antineoplastic Agents, Alkylating; Aquaporins; Cell Line, Tumor; Drug Resistance, Neoplasm; | 2018 |
Plasmas for Treating Cancer: Opportunities for Adaptive and Self-Adaptive Approaches.
Topics: Animals; Antineoplastic Agents, Alkylating; Aquaporins; Cell Line, Tumor; Drug Resistance, Neoplasm; | 2018 |
Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemor | 2018 |
Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemor | 2018 |
Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemor | 2018 |
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimum | 2018 |
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimum | 2018 |
Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
Topics: Antineoplastic Agents; Dacarbazine; Health Expenditures; Health Resources; Humans; Indoles; Ipilimum | 2018 |
Efficacy of nab-paclitaxel in treating metastatic melanoma.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Tem | 2019 |
Efficacy of nab-paclitaxel in treating metastatic melanoma.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Tem | 2019 |
Efficacy of nab-paclitaxel in treating metastatic melanoma.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Dacarbazine; Humans; Melanoma; Paclitaxel; Tem | 2019 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; D | 2013 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; D | 2013 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; D | 2013 |
Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Huma | 2014 |
Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Huma | 2014 |
Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Huma | 2014 |
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Dac | 2013 |
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Dac | 2013 |
Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Dac | 2013 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dac | 2014 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dac | 2014 |
What is the role of chemotherapy in the treatment of melanoma?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carboplatin; Cisplatin; Clinical Trials as Topic; Dac | 2014 |
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; | 2014 |
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; | 2014 |
Current systemic therapies for melanoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Dacarbazine; Humans; | 2014 |
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Immunologic Factors; Im | 2015 |
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Immunologic Factors; Im | 2015 |
The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Dacarbazine; Humans; Immunologic Factors; Im | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
Chemotherapy for Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Melanoma; Neoplasm | 2016 |
Chemotherapy for Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Melanoma; Neoplasm | 2016 |
Chemotherapy for Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Humans; Melanoma; Neoplasm | 2016 |
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Sur | 2016 |
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Sur | 2016 |
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; Dermatologic Sur | 2016 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; | 2009 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; | 2009 |
Multiple intracranial melanoma metastases: case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; | 2009 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Topics: Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; Drug Adm | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2010 |
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2010 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2011 |
[Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Damage; Humans; Immunoth | 2011 |
[Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Damage; Humans; Immunoth | 2011 |
[Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Damage; Humans; Immunoth | 2011 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
Temozolomide and unusual indications: review of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Melanoma; N | 2013 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modali | 2013 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modali | 2013 |
[Therapeutic strategies and systemic treatment of brain melanoma metastases].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Combined Modali | 2013 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Temozolomide: a novel oral alkylating agent.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administ | 2001 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmu | 2002 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmu | 2002 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmu | 2002 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2003 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2003 |
[Treatment of melanoma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2003 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; | 2004 |
Management of brain metastases in patients with melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System; Chemotherapy, Adjuvant; | 2004 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Da | 2004 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Da | 2004 |
The role of taxanes in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Da | 2004 |
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
Management of metastatic cutaneous melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clini | 2004 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
[Chemotherapy for brain metastases].
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasm | 2005 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; | 2007 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; | 2007 |
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; | 2007 |
Temozolomide for the treatment of metastatic melanoma: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2007 |
Temozolomide for the treatment of metastatic melanoma: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2007 |
Temozolomide for the treatment of metastatic melanoma: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2007 |
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; CD4-Positive T-Lymphocytes; Cell Line, | 2008 |
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; CD4-Positive T-Lymphocytes; Cell Line, | 2008 |
Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; CD4-Positive T-Lymphocytes; Cell Line, | 2008 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Com | 1995 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Com | 1995 |
Systemic treatments for advanced cutaneous melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Com | 1995 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; D | 2000 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; D | 2000 |
Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Biological Availability; Brain Neoplasms; D | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
96 trials available for temozolomide and Melanoma
| Article | Year |
|---|---|
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Melanoma; Pyridines; Skin Neo | 2022 |
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Melanoma; Pyridines; Skin Neo | 2022 |
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunotherapy; Melanoma; Pyridines; Skin Neo | 2022 |
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Melanoma; Melanoma, Cutaneous Malignan | 2023 |
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Melanoma; Melanoma, Cutaneous Malignan | 2023 |
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Melanoma; Melanoma, Cutaneous Malignan | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Me | 2017 |
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Me | 2017 |
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Dacarbazine; Female; Humans; Ipilimumab; Male; Me | 2017 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2013 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2013 |
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2013 |
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2013 |
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2013 |
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2013 |
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose- | 2014 |
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose- | 2014 |
Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dacarbazine; Dose- | 2014 |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2014 |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2014 |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2014 |
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazi | 2014 |
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazi | 2014 |
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dacarbazi | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Daca | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Daca | 2014 |
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Daca | 2014 |
Quality of life after isolated limb infusion for in-transit melanoma of the extremity.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extr | 2015 |
Quality of life after isolated limb infusion for in-transit melanoma of the extremity.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extr | 2015 |
Quality of life after isolated limb infusion for in-transit melanoma of the extremity.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Extr | 2015 |
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methyla | 2015 |
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methyla | 2015 |
A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; DNA Methyla | 2015 |
Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dog Diseases; Do | 2016 |
Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dog Diseases; Do | 2016 |
Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Dog Diseases; Do | 2016 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; | 2015 |
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Re | 2015 |
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Re | 2015 |
Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Re | 2015 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2016 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2016 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2016 |
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2016 |
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Co | 2017 |
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Co | 2017 |
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; CD11c Antigen; CD3 Co | 2017 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2008 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2008 |
A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2008 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com | 2008 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com | 2008 |
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com | 2008 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Stud | 2009 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Stud | 2009 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Stud | 2009 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationsh | 2009 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationsh | 2009 |
A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Child; Dacarbazine; Dose-Response Relationsh | 2009 |
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replica | 2009 |
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replica | 2009 |
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replica | 2009 |
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Ch | 2009 |
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Ch | 2009 |
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Ch | 2009 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2010 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; | 2010 |
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemokines; | 2010 |
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2010 |
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2010 |
Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2010 |
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; DNA Modifi | 2010 |
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; DNA Modifi | 2010 |
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Dacarbazine; DNA Methylation; DNA Modifi | 2010 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazin | 2011 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazin | 2011 |
Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dacarbazin | 2011 |
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Cytokines; Dacarbazine; Humans; Imm | 2011 |
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Cytokines; Dacarbazine; Humans; Imm | 2011 |
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Cytokines; Dacarbazine; Humans; Imm | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).
Topics: Aged; Area Under Curve; Dacarbazine; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; D | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; D | 2011 |
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; D | 2011 |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2012 |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2012 |
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2012 |
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; | 2011 |
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; | 2011 |
Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dacarbazine; Disease-Free Survival; | 2011 |
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Da | 2012 |
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Da | 2012 |
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Da | 2012 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apo | 2013 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apo | 2013 |
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Apo | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dac | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dac | 2013 |
Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dac | 2013 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2014 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2014 |
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2014 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2002 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2002 |
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2002 |
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2003 |
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2003 |
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease | 2003 |
Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Magnetic Reso | 2002 |
Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Magnetic Reso | 2002 |
Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Humans; Magnetic Reso | 2002 |
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; | 2003 |
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; | 2003 |
Phase II evaluation of temozolomide in metastatic choroidal melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2003 |
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca | 2003 |
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca | 2003 |
A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca | 2003 |
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; | 2003 |
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; | 2003 |
Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cognition; | 2003 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine | 2004 |
Temozolomide as prophylaxis for melanoma brain metastases.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2004 |
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dis | 2004 |
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2004 |
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2004 |
Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; H | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; H | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; H | 2004 |
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Topics: Adult; Aged; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interferon-a | 2004 |
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Topics: Adult; Aged; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interferon-a | 2004 |
Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup.
Topics: Adult; Aged; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Interferon-a | 2004 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; | 2005 |
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; | 2005 |
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Female; | 2005 |
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2005 |
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2005 |
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Dam | 2005 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Dam | 2005 |
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Comet Assay; Dacarbazine; DNA Dam | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2005 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progres | 2005 |
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progres | 2005 |
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progres | 2005 |
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dac | 2005 |
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dac | 2005 |
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dac | 2005 |
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; F | 2005 |
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; F | 2005 |
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Dacarbazine; F | 2005 |
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarb | 2005 |
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarb | 2005 |
Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarb | 2005 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neopla | 2005 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neopla | 2005 |
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; DNA Methylation; DNA, Neopla | 2005 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2006 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2006 |
A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolomide (Temodal), interferon-alfa and interleukin-2 for metastatic melanoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dacarbazine | 2006 |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neo | 2006 |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neo | 2006 |
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Eye Neo | 2006 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema | 2006 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema | 2006 |
Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Fema | 2006 |
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologi | 2006 |
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologi | 2006 |
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Immunologi | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhi | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb | 2007 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carci | 2007 |
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Fem | 2008 |
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Fem | 2008 |
Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Fem | 2008 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Daca | 2008 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Daca | 2008 |
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Daca | 2008 |
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Human | 2008 |
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Human | 2008 |
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Vaccines; Dacarbazine; Female; Heat-Shock Proteins; Human | 2008 |
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; I | 2008 |
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; I | 2008 |
Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; I | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2008 |
Phase II study of extended-dose temozolomide in patients with melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; CD3 Co | 2008 |
Phase II study of extended-dose temozolomide in patients with melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; CD3 Co | 2008 |
Phase II study of extended-dose temozolomide in patients with melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; CD3 Co | 2008 |
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melan | 1995 |
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melan | 1995 |
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Leukopenia; Male; Melan | 1995 |
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Leu | 1994 |
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Leu | 1994 |
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Kinetics; Leu | 1994 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barri | 1998 |
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Female; Humans; Leukocytes, Mononucle | 1998 |
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Female; Humans; Leukocytes, Mononucle | 1998 |
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Female; Humans; Leukocytes, Mononucle | 1998 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Resp | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Biological Availability; Brain | 1999 |
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; | 2000 |
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; | 2000 |
Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; | 2000 |
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration | 2000 |
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration | 2000 |
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration | 2000 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2002 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2002 |
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality T | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality T | 2002 |
Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality T | 2002 |
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; | 2002 |
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; | 2002 |
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; | 2002 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Dacar | 1992 |
184 other studies available for temozolomide and Melanoma
| Article | Year |
|---|---|
Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines.
Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Respon | 2013 |
Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines.
Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Respon | 2013 |
Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines.
Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Respon | 2013 |
The selective cytotoxicity of new triazene compounds to human melanoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dimerization; Drug Screening Assays, Antitumor; Ha | 2017 |
The selective cytotoxicity of new triazene compounds to human melanoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dimerization; Drug Screening Assays, Antitumor; Ha | 2017 |
The selective cytotoxicity of new triazene compounds to human melanoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dimerization; Drug Screening Assays, Antitumor; Ha | 2017 |
Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy.
Topics: Drug Hypersensitivity Syndrome; Exanthema; Glioblastoma; Humans; Male; Melanoma; Middle Aged; Temozo | 2022 |
Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy.
Topics: Drug Hypersensitivity Syndrome; Exanthema; Glioblastoma; Humans; Male; Melanoma; Middle Aged; Temozo | 2022 |
Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy.
Topics: Drug Hypersensitivity Syndrome; Exanthema; Glioblastoma; Humans; Male; Melanoma; Middle Aged; Temozo | 2022 |
MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Glioma; Humans; Me | 2023 |
MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Glioma; Humans; Me | 2023 |
MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Glioma; Humans; Me | 2023 |
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Melanoma; Mice; Mice, Inb | 2023 |
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Melanoma; Mice; Mice, Inb | 2023 |
Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Female; Glioma; Humans; Melanoma; Mice; Mice, Inb | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolom | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolom | 2023 |
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine; Humans; Melanoma; Mice; Temozolom | 2023 |
Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma.
Topics: Carrier Proteins; Cisplatin; Humans; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms; Temozo | 2023 |
Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma.
Topics: Carrier Proteins; Cisplatin; Humans; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms; Temozo | 2023 |
Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma.
Topics: Carrier Proteins; Cisplatin; Humans; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms; Temozo | 2023 |
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Ipilimumab; Male; Mel | 2023 |
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Ipilimumab; Male; Mel | 2023 |
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Ipilimumab; Male; Mel | 2023 |
Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Drug | 2019 |
Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Drug | 2019 |
Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Drug | 2019 |
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studi | 2020 |
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studi | 2020 |
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studi | 2020 |
Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Cell-Derived Micro | 2019 |
Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Cell-Derived Micro | 2019 |
Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Cell-Derived Micro | 2019 |
Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma.
Topics: Animals; Apoptosis; Biocompatible Materials; Cell Line; Chitosan; Down-Regulation; Drug Carriers; Dr | 2020 |
Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma.
Topics: Animals; Apoptosis; Biocompatible Materials; Cell Line; Chitosan; Down-Regulation; Drug Carriers; Dr | 2020 |
Discovering pH triggered charge rebound surface modulated topical nanotherapy against aggressive skin papilloma.
Topics: Animals; Apoptosis; Biocompatible Materials; Cell Line; Chitosan; Down-Regulation; Drug Carriers; Dr | 2020 |
Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Imm | 2020 |
Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Imm | 2020 |
Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Imm | 2020 |
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Follow-Up Studies; H | 2021 |
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Follow-Up Studies; H | 2021 |
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Follow-Up Studies; H | 2021 |
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Spindle cell melanoma coexisting with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare collision tumor in multiple sites.
Topics: Aged, 80 and over; Antigens, CD20; Antineoplastic Agents, Alkylating; Biopsy; CD5 Antigens; Fatal Ou | 2020 |
Spindle cell melanoma coexisting with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare collision tumor in multiple sites.
Topics: Aged, 80 and over; Antigens, CD20; Antineoplastic Agents, Alkylating; Biopsy; CD5 Antigens; Fatal Ou | 2020 |
Spindle cell melanoma coexisting with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare collision tumor in multiple sites.
Topics: Aged, 80 and over; Antigens, CD20; Antineoplastic Agents, Alkylating; Biopsy; CD5 Antigens; Fatal Ou | 2020 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell L | 2017 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell L | 2017 |
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell L | 2017 |
Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, | 2017 |
Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, | 2017 |
Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, | 2017 |
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Heterografts; Humans; In | 2017 |
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Heterografts; Humans; In | 2017 |
Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Heterografts; Humans; In | 2017 |
MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Dacarbazine; Drug Resista | 2017 |
MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Dacarbazine; Drug Resista | 2017 |
MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Dacarbazine; Drug Resista | 2017 |
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; | 2018 |
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; | 2018 |
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; | 2018 |
Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Humans; Hyaluro | 2018 |
Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Humans; Hyaluro | 2018 |
Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Humans; Hyaluro | 2018 |
Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Topics: Animals; Apoptosis; Autophagy; Caspase 7; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chape | 2018 |
Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Topics: Animals; Apoptosis; Autophagy; Caspase 7; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chape | 2018 |
Inhibition of endoplasmic reticulum stress-induced autophagy sensitizes melanoma cells to temozolomide treatment.
Topics: Animals; Apoptosis; Autophagy; Caspase 7; Cell Line, Tumor; Dacarbazine; Endoplasmic Reticulum Chape | 2018 |
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbon-Sulfur | 2018 |
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbon-Sulfur | 2018 |
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbon-Sulfur | 2018 |
Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line; Combined Modality Therapy; Coxs | 2018 |
Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line; Combined Modality Therapy; Coxs | 2018 |
Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line; Combined Modality Therapy; Coxs | 2018 |
Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: A role for autophagy and premature senescence.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chloroquine; Drug R | 2019 |
Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: A role for autophagy and premature senescence.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chloroquine; Drug R | 2019 |
Trehalose inhibits cell proliferation and amplifies long-term temozolomide- and radiation-induced cytotoxicity in melanoma cells: A role for autophagy and premature senescence.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chloroquine; Drug R | 2019 |
The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, I | 2019 |
The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, I | 2019 |
The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, I | 2019 |
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Female; Humans; Male; Me | 2019 |
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Female; Humans; Male; Me | 2019 |
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Female; Humans; Male; Me | 2019 |
Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy.
Topics: Autophagy; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA | 2019 |
Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy.
Topics: Autophagy; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA | 2019 |
Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy.
Topics: Autophagy; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA | 2019 |
Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways.
Topics: Bee Venoms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Gen | 2019 |
Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways.
Topics: Bee Venoms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Gen | 2019 |
Bee Venom and Its Peptide Component Melittin Suppress Growth and Migration of Melanoma Cells via Inhibition of PI3K/AKT/mTOR and MAPK Pathways.
Topics: Bee Venoms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Gen | 2019 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2014 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2014 |
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2014 |
A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Prol | 2013 |
A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Prol | 2013 |
A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Prol | 2013 |
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Fe | 2013 |
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Fe | 2013 |
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Dacarbazine; Fe | 2013 |
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Topics: Adult; Aged; Cancer Vaccines; CTLA-4 Antigen; Dacarbazine; Dendritic Cells; Female; Forkhead Transcr | 2013 |
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Topics: Adult; Aged; Cancer Vaccines; CTLA-4 Antigen; Dacarbazine; Dendritic Cells; Female; Forkhead Transcr | 2013 |
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Topics: Adult; Aged; Cancer Vaccines; CTLA-4 Antigen; Dacarbazine; Dendritic Cells; Female; Forkhead Transcr | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Da | 2013 |
Selumetinib shows promise in metastatic uveal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; | 2013 |
Selumetinib shows promise in metastatic uveal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; | 2013 |
Selumetinib shows promise in metastatic uveal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; | 2013 |
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpo | 2013 |
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpo | 2013 |
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpo | 2013 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Adminis | 2014 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Adminis | 2014 |
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Drug Adminis | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
[Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Combined Modality Th | 2014 |
FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Fluorodeoxyg | 2014 |
FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Fluorodeoxyg | 2014 |
FDG-PET/CT assessment of differential chemotherapy effects upon skeletal muscle metabolism in patients with melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Fluorodeoxyg | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2014 |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2014 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazi | 2014 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazi | 2014 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazi | 2014 |
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeabil | 2015 |
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeabil | 2015 |
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeabil | 2015 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; | 2014 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; | 2014 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; | 2014 |
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzy | 2014 |
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzy | 2014 |
Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA; DNA Methylation; Enzy | 2014 |
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Topics: Animals; Apoptosis; Cell Survival; Chemokines; Dacarbazine; Disease Models, Animal; Drug Synergism; | 2014 |
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Topics: Animals; Apoptosis; Cell Survival; Chemokines; Dacarbazine; Disease Models, Animal; Drug Synergism; | 2014 |
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Topics: Animals; Apoptosis; Cell Survival; Chemokines; Dacarbazine; Disease Models, Animal; Drug Synergism; | 2014 |
Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Prolife | 2015 |
Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Prolife | 2015 |
Enhanced antitumor efficacy of a novel oncolytic adenovirus combined with temozolomide in the treatment of melanoma in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Prolife | 2015 |
Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Forkhead Box Protein | 2014 |
Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Forkhead Box Protein | 2014 |
Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; Forkhead Box Protein | 2014 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Daca | 2015 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Daca | 2015 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Daca | 2015 |
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2015 |
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2015 |
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2015 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose | 2014 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose | 2014 |
Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Colitis; Dacarbazine; Fluorodeoxyglucose | 2014 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Human | 2014 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Human | 2014 |
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarbazine; Drug Synergism; Human | 2014 |
Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Dacarbazine; Hum | 2015 |
Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Dacarbazine; Hum | 2015 |
Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Dacarbazine; Hum | 2015 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2015 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2015 |
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; | 2015 |
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA M | 2015 |
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA M | 2015 |
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA M | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, N | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, N | 2015 |
c-Myc modulation: a key role in melanoma drug response.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; Doxorubicin; Drug Resistance, N | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immun | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immun | 2015 |
Comparative healthcare costs in patients with metastatic melanoma in the USA.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Dacarbazine; Female; Health Care Costs; Humans; Immun | 2015 |
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tu | 2015 |
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tu | 2015 |
IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tu | 2015 |
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease-Free | 2016 |
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease-Free | 2016 |
Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Disease-Free | 2016 |
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitati | 2016 |
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitati | 2016 |
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitati | 2016 |
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Ki | 2016 |
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Ki | 2016 |
Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.
Topics: Alkylating Agents; Apoptosis; Bortezomib; Cell Cycle Checkpoints; Cell Division; Cyclin-Dependent Ki | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2016 |
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, | 2016 |
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, | 2016 |
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Melanoma; Mice; Mice, | 2016 |
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2016 |
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2016 |
Evaluating the cytotoxic effects of the water extracts of four anticancer herbs against human malignant melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2016 |
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Prolife | 2017 |
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Prolife | 2017 |
Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Prolife | 2017 |
Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dendrimers; Drug Delivery Systems; | 2017 |
Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dendrimers; Drug Delivery Systems; | 2017 |
Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Dendrimers; Drug Delivery Systems; | 2017 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Ind | 2017 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Ind | 2017 |
Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dacarbazine; Databases, Factual; Female; Humans; Ind | 2017 |
An unusual pituitary stalk lesion: What is the place of surgery?
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes | 2016 |
An unusual pituitary stalk lesion: What is the place of surgery?
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes | 2016 |
An unusual pituitary stalk lesion: What is the place of surgery?
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Diabetes | 2016 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; En | 2008 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; En | 2008 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; En | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; | 2008 |
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cel | 2008 |
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cel | 2008 |
Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Cell Line, Tumor; Cel | 2008 |
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relation | 2008 |
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relation | 2008 |
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Dose-Response Relation | 2008 |
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Enzyme Inhib | 2009 |
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Enzyme Inhib | 2009 |
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Enzyme Inhib | 2009 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Typ | 2009 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Typ | 2009 |
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Typ | 2009 |
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2009 |
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2009 |
Genomic and molecular profiling predicts response to temozolomide in melanoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2009 |
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Surv | 2009 |
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Surv | 2009 |
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Surv | 2009 |
Primary malignant melanoma of the vagina.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-a | 2009 |
Primary malignant melanoma of the vagina.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-a | 2009 |
Primary malignant melanoma of the vagina.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Female; Humans; Interferon-a | 2009 |
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; | 2009 |
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; | 2009 |
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.
Topics: Alkylating Agents; Brain Neoplasms; Breast Neoplasms; Dacarbazine; DNA Methylation; DNA Modification | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Sys | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Sys | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Sys | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazi | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazi | 2009 |
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dacarbazi | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell P | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell P | 2009 |
Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell P | 2009 |
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Ce | 2009 |
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Ce | 2009 |
Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
Topics: Aged; Antineoplastic Agents, Alkylating; Azathioprine; Carcinoma, Basal Cell; Carcinoma, Squamous Ce | 2009 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamid | 2010 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamid | 2010 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamid | 2010 |
Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylat | 2009 |
Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylat | 2009 |
Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylat | 2009 |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
Topics: Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Screening Assays, | 2009 |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
Topics: Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Screening Assays, | 2009 |
Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells.
Topics: Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Drug Screening Assays, | 2009 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; | 2010 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; | 2010 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; | 2010 |
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell | 2010 |
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell | 2010 |
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Brain metastases from melanoma: is there a role for concurrent temozolomide in addition to whole brain radiation therapy?
Topics: Administration, Oral; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modalit | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neo | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neo | 2010 |
Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neo | 2010 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarb | 2010 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarb | 2010 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarb | 2010 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gen | 2010 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gen | 2010 |
Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dacarbazine; Female; Gen | 2010 |
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening As | 2010 |
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening As | 2010 |
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening As | 2010 |
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male | 2010 |
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male | 2010 |
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Male | 2010 |
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; C | 2010 |
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; C | 2010 |
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; C | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed | 2010 |
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed | 2010 |
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
Topics: Antineoplastic Agents; Base Sequence; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA | 2010 |
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
Topics: Antineoplastic Agents; Base Sequence; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA | 2010 |
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
Topics: Antineoplastic Agents; Base Sequence; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA | 2010 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Di | 2012 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Di | 2012 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Di | 2012 |
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms | 2010 |
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms | 2010 |
Positron emission tomography/computed tomography: use for initial staging of malignant melanoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Axilla; Dacarbazine; Fatal Outcome; Humans; Liver Neoplasms | 2010 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Rela | 2010 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Rela | 2010 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Rela | 2010 |
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 | 2011 |
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 | 2011 |
siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; G1 | 2011 |
Down-regulation of O6-methylguanine-DNA methyl transferase enhances the effect of temozolomide in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Humans; Melanoma; | 2011 |
Down-regulation of O6-methylguanine-DNA methyl transferase enhances the effect of temozolomide in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Humans; Melanoma; | 2011 |
Down-regulation of O6-methylguanine-DNA methyl transferase enhances the effect of temozolomide in melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Humans; Melanoma; | 2011 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2010 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2010 |
High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2010 |
Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; NF-kappa B; Placenta Growth Factor; Pregna | 2011 |
Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; NF-kappa B; Placenta Growth Factor; Pregna | 2011 |
Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.
Topics: Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; NF-kappa B; Placenta Growth Factor; Pregna | 2011 |
Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Autoantibodies; Autoantigens; Blotting, Western; C | 2011 |
Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Autoantibodies; Autoantigens; Blotting, Western; C | 2011 |
Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Autoantibodies; Autoantigens; Blotting, Western; C | 2011 |
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacar | 2011 |
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacar | 2011 |
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacar | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; C | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; C | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; C | 2011 |
Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; | 2011 |
Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; | 2011 |
Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; | 2011 |
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Dacarbazine; DNA Breaks, Dou | 2011 |
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Dacarbazine; DNA Breaks, Dou | 2011 |
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Dacarbazine; DNA Breaks, Dou | 2011 |
NRAS-mutant melanoma: response to chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; | 2011 |
NRAS-mutant melanoma: response to chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; | 2011 |
NRAS-mutant melanoma: response to chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Genes, ras; Humans; | 2011 |
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immu | 2011 |
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immu | 2011 |
Melanoma-associated retinopathy: a presenting sign of metastatic disease.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Fine-Needle; Dacarbazine; Follow-Up Studies; Humans; Immu | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, | 2011 |
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dacarbazine; | 2011 |
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dacarbazine; | 2011 |
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dacarbazine; | 2011 |
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Topics: Alkylating Agents; Animals; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; D | 2011 |
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Topics: Alkylating Agents; Animals; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; D | 2011 |
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Topics: Alkylating Agents; Animals; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; D | 2011 |
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; | 2011 |
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; | 2011 |
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.
Topics: Animals; Cell Movement; Chemokine CCL5; Chemokine CXCL9; Chemokines; Dacarbazine; Humans; Melanoma; | 2011 |
Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, N | 2012 |
Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, N | 2012 |
Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, N | 2012 |
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozy | 2011 |
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozy | 2011 |
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Topics: Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Dacarbazine; Exome; Humans; Loss of Heterozy | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; D | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; D | 2011 |
Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; D | 2011 |
Targeting protein-trafficking pathways alters melanoma treatment sensitivity.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; D | 2012 |
Targeting protein-trafficking pathways alters melanoma treatment sensitivity.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; D | 2012 |
Targeting protein-trafficking pathways alters melanoma treatment sensitivity.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Dacarbazine; D | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bec | 2012 |
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2012 |
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2012 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, T | 2009 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, T | 2009 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, T | 2009 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosi | 2012 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosi | 2012 |
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde Oxidoreductases; Animals; Apoptosi | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2012 |
Survival over 6 years in a patient with brain metastases from melanoma treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2012 |
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Femal | 2013 |
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Femal | 2013 |
XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Resistance, Neoplasm; Femal | 2013 |
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Epirub | 2012 |
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Epirub | 2012 |
Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Epirub | 2012 |
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free | 2013 |
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free | 2013 |
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free | 2013 |
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Topics: Adenosine Triphosphatases; Animals; Cell Division; Dacarbazine; Disease Models, Animal; Guanine; Hum | 2002 |
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Topics: Adenosine Triphosphatases; Animals; Cell Division; Dacarbazine; Disease Models, Animal; Guanine; Hum | 2002 |
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Topics: Adenosine Triphosphatases; Animals; Cell Division; Dacarbazine; Disease Models, Animal; Guanine; Hum | 2002 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; D | 2002 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; D | 2002 |
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Cisplatin; D | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
[Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neopl | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2002 |
[Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Humans; | 2002 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combina | 2003 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combina | 2003 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combina | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DN | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DN | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DN | 2003 |
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Co | 2003 |
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Co | 2003 |
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survival; Drug Therapy, Co | 2003 |
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Rep | 2003 |
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Rep | 2003 |
DNA repair enzymes and cytotoxic effects of temozolomide: comparative studies between tumor cells and normal cells of the immune system.
Topics: Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Cell Division; Dacarbazine; DNA Damage; DNA Rep | 2003 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; M | 2004 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; M | 2004 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; M | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacar | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacar | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacar | 2004 |
Quality of life, at what cost?
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; | 2003 |
Quality of life, at what cost?
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; | 2003 |
Quality of life, at what cost?
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dacarbazine; Drug Costs; Humans; Melanoma; | 2003 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |
Metastatic malignant melanoma presenting as a cavernous sinus syndrome.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Blepharoptosis; Cavernous Sinus Thrombosis; Cranial | 2004 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2004 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2004 |
[Temozolomide in patients with melanoma brain metastases treated with whole brain irradiation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2004 |
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; | 2004 |
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; | 2004 |
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Female; Humans; | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance | 2004 |
Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Humans; Magnetic Resonance | 2004 |
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dru | 2004 |
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dru | 2004 |
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dru | 2004 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2004 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2004 |
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Per | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Per | 2004 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Per | 2004 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2004 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2004 |
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazi | 2004 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Cardiac metastasis of melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Heart Neoplasms; H | 2005 |
Cardiac metastasis of melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Heart Neoplasms; H | 2005 |
Cardiac metastasis of melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Choroid Neoplasms; Dacarbazine; Female; Heart Neoplasms; H | 2005 |
O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Re | 2006 |
O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Re | 2006 |
O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
Topics: Antineoplastic Agents; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Re | 2006 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cere | 2005 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cere | 2005 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cere | 2005 |
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 2005 |
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 2005 |
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro | 2005 |
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; C | 2006 |
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; C | 2006 |
Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Cell Membrane Permeability; C | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2006 |
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2006 |
Primary malignant melanoma of the lung: a case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; L | 2006 |
Primary malignant melanoma of the lung: a case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; L | 2006 |
Primary malignant melanoma of the lung: a case report and review of the literature.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; Fluorodeoxyglucose F18; Humans; L | 2006 |
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2006 |
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2006 |
Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2006 |
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neopl | 2006 |
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neopl | 2006 |
[Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Dermatitis, Phototoxic; Humans; Melanoma; Skin Neopl | 2006 |
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance | 2006 |
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance | 2006 |
A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Topics: Antineoplastic Agents; Base Pair Mismatch; Dacarbazine; DNA Methylation; DNA Repair; Drug Resistance | 2006 |
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proli | 2007 |
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proli | 2007 |
Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cancer Vaccines; Cell Line, Tumor; Cell Proli | 2007 |
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expr | 2007 |
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expr | 2007 |
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expr | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |
Radiochemotherapy for brain metastasis: how to define a role for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; H | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; H | 2007 |
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; H | 2007 |
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug | 2007 |
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug | 2007 |
Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE).
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Detergents; Drug | 2007 |
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvan | 2007 |
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvan | 2007 |
Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Chemotherapy, Adjuvan | 2007 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms | 2008 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms | 2008 |
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms | 2008 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dac | 2007 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dac | 2007 |
O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Blotting, Western; Dac | 2007 |
Temozolomide induces senescence but not apoptosis in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzothiazoles; Cell Division; Cellular Senescence; Da | 2007 |
Temozolomide induces senescence but not apoptosis in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzothiazoles; Cell Division; Cellular Senescence; Da | 2007 |
Temozolomide induces senescence but not apoptosis in human melanoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Benzothiazoles; Cell Division; Cellular Senescence; Da | 2007 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Ski | 2008 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Ski | 2008 |
Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Eruptions; Female; Humans; Melanoma; Ski | 2008 |
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; | 2008 |
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; | 2008 |
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Synergism; | 2008 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Human | 2008 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Human | 2008 |
A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Dacarbazine; Ecchymosis; Female; Human | 2008 |
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Cadherins; Dacarbazine; DNA Adducts; Humans; Immunothera | 2008 |
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Cadherins; Dacarbazine; DNA Adducts; Humans; Immunothera | 2008 |
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Cadherins; Dacarbazine; DNA Adducts; Humans; Immunothera | 2008 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine | 1993 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine | 1993 |
From triazines and triazenes to temozolomide.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Chemistry, Pharmaceutical; Dacarbazine | 1993 |
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; | 1996 |
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; | 1996 |
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase.
Topics: Animals; Cell Compartmentation; Cell Nucleus; Cytoplasm; Dacarbazine; DNA Repair; Enzyme Inhibitors; | 1996 |
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Temozolomide for advanced, metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quali | 2000 |
Temozolomide for advanced, metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quali | 2000 |
Temozolomide for advanced, metastatic melanoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Melanoma; Proportional Hazards Models; Quali | 2000 |
What's new in the treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Hu | 2000 |
What's new in the treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Hu | 2000 |
What's new in the treatment of melanoma?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Hu | 2000 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re | 2001 |
Treatment of brain metastases of malignant melanoma with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Lung Neoplasms; Magnetic Re | 2001 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru | 2001 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru | 2001 |
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru | 2001 |